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Statement on the Impact of Covid19 
 
The coronavirus 2019 pandemic had significant impacts across NHS Scotland. The NHS board 
and service in which our research was situated adapted its structure, policies, and ways of 
working in response to the pandemic and associated regulations. Covid19 and its impacts led 
to reconsideration of this major research project’s design and practicalities. 
Our study initially aimed to recruit a larger sample of service user participants and compare 
pre- and post-intervention measures; however, this was not feasible within adapted 
timelines. We have collected usable data towards the intended work, but the nature and 
amount of the data differs from what was planned in initial proposals. This work has therefore 
been submitted under Acceptable Portfolio Variation 1 – containing a reduced amount of data 
from what was intended.  
In Chapter 2, we therefore present preliminary data for a project that is ongoing; specifically 
reporting initial summary quantitative data and a qualitative analysis of keyworker clinicians’ 
expectations for digital CBT intervention for insomnia. A preliminary logic model is described, 
developed from the available data. Limitations of the analysis and resulting interpretations 
are clearly explored.   
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Chapter 1. The Prevalence of Insomnia in Nonaffective Psychosis and its 
Relationship to Symptomatology: A Systematic Review and Meta-Analysis 
 









Dysfunction in the amount, timing, quality, or characteristics of sleep are common in people 
experiencing nonaffective psychosis. Sleep dysfunction occurs during prodromal phases of 
psychosis, in people experiencing a first episode, and in established psychosis. Insomnia, 
which describes a difficulty initiating or maintaining sleep, is particularly common. The 
prevalence of insomnia in nonaffective psychosis is not established. We present a systematic 
review and meta-analysis of i) the prevalence of insomnia disorder and symptoms in 
nonaffective psychosis and ii) its relationship to psychosis symptomatology. We searched 
electronic databases to identify articles published prior to March 31st 2021. Eighteen studies 
were included. Fifteen reported an estimated prevalence of insomnia and ten described the 
relationship between insomnia and psychosis symptoms. Random-effects meta-analyses 
indicated a pooled prevalence of insomnia symptoms of 36.5% (95%CI=27.2–46.4%; n=10) for 
those studies primarily aiming to establish prevalence and 34.8% (95%CI=27.4–42.6%; n=15) 
for all studies reporting a prevalence statistic. For studies using the Insomnia Severity Index, 
pooled prevalence was 45.6% (95%CI=32–59.6%, n=7). More severe insomnia was related to 
increased positive symptoms of psychosis and mood difficulties. Included papers were highly 
variable in methods and resulting prevalence estimates. Further research investigating the 
prevalence of insomnia, symptom correlates, and the relationship to treatment protocols 
across the spectrum of nonaffective psychosis would be beneficial to inform clinical practice. 






Psychosis describes a group of symptoms which include disorganised thoughts and speech, 
voice-hearing, visual hallucinations, unusual strongly held beliefs (together referred to as 
‘positive symptoms’); alogia, avolition, asociality, anhedonia and reduced affect expression 
(together referred to as ‘negative symptoms’; Wigman et al., 2011). Nonaffective psychosis 
describes a group of diagnoses including schizophrenia spectrum disorders, schizophreniform 
disorder, schizoaffective disorder, delusional disorder, and psychosis not otherwise specified 
(American Psychiatric Association, 2013). They are differentiated from affective psychoses 
(e.g. bipolar 1 or postpartum psychosis) by the extent to which mood disorder is the core 
feature. Some theoretical approaches consider all psychosis diagnoses or symptoms as part 
of an underlying continuum (Craddock and Owen, 2010). Previous work exploring 
nonaffective psychosis included people at ultra-high risk of developing psychosis or 
experiencing emerging initial symptoms (referred to as prodromal psychosis; Olsen and 
Rosenbaum, 2006), people experiencing a first episode or early psychosis (Birchwood et al., 
1998), or people with an established nonaffective psychosis spectrum diagnosis.  
Insomnia describes a set of symptoms including difficulties with initiating sleep, maintaining 
sleep and early morning wakening, which have a negative impact on subjective sleep quality, 
functioning, and/or emotions. Diagnosis of insomnia disorder requires these features to be 
relatively severe, occurring at least three times per week over three months, and not better 
explained by inadequate sleep opportunity nor another sleep disorder (American Psychiatric 
Association, 2013). Sleep dysfunction has become a focus of research in psychosis, as a 
potential causal mechanism and treatment target (Waite et al., 2020). Several reviews and 
experimental studies have examined sleep disorder in nonaffective psychosis (Chouinard et 
al., 2004, Reeve et al., 2015, Waite et al., 2020), including in prodromal subpopulations 
(Goines et al., 2019, Poe et al., 2017) and in first episode psychosis (Davies et al., 2017). Sleep 
disorder is common, related to more severe psychosis symptomatology and poorer quality of 
life, and often remains untreated (Kaskie et al., 2017). Of the sleep disorders, insomnia is 
seemingly particularly prevalent (Reeve et al., 2015, Waite et al., 2020). Insomnia has been 
proposed to act as a mediator in many psychiatric conditions, including psychosis (Dolsen et 
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al., 2014). Systematic review of the prevalence of insomnia in prodromal psychosis, first 
episode, or established nonaffective psychosis has not been undertaken. 
Establishing the prevalence of insomnia and its relationship to symptoms associated with 
psychosis may raise awareness of this unmet need, enabling health services to prioritise 
comprehensive assessment and treatment of insomnia in relevant services, and providing a 
stronger basis to estimate requirements of future studies to determine insomnia prevalence 
in non-affective psychosis. Therefore, this systematic review and meta-analysis primarily aims 
to establish the prevalence of insomnia or insomnia symptoms in people with nonaffective 
psychosis. The secondary aims are to explore its relationship to symptomology. We intend to 
review published works assessing people experiencing prodromal psychosis, first episode 






A systematic review was conducted according to guidance provided in the PRISMA statement 
(Page et al., 2021). The protocol for this review was established but not published prior to 
beginning data extraction (Appendix 1.2.). 
 
1.3.1. Search Strategy  
Searches (Appendix 1.3.) were carried out across four electronic databases (Medline R, 
Embase, APA PsychInfo and CINAHL) for English language publications, where the title or 
abstract contained the following terms: (insomn* OR sleep OR sleep initiat* OR sleep 
maintain* OR sleeplessness) AND ((schizo* OR psychos?s OR psychotic OR Delus* OR 
Hallucinat*) OR (first?episode OR early psychosis) OR (Prodrom* OR ultra?high?risk OR 
at?risk?mental?state OR clinical?high?risk)), published from database beginning until 31 
March 2021.  
Duplicate records were removed from search results using Endnote X9.3.3. (2019; Clarivate 
Analytics, London, UK) de-duplification and hand screening. Titles and abstracts were 
screened, and irrelevant records were removed. This process was repeated twice to reduce 
the risk of records being removed erroneously. Records passing title and abstract screening 
were reviewed as full-text, to ascertain whether they fulfilled inclusion and exclusion criteria. 
The reference lists of relevant papers were hand-scanned for further citations, which were 
screened as full-text. Where studies were excluded at full-text screening, the reason for 
exclusion was noted. 
 
1.3.2. Eligibility  
1.3.2.1. Inclusion Criteria 
Included papers reported quantitative studies published in English in peer-reviewed journals 
that included i) people experiencing prodromal psychosis, defined by the comprehensive 
assessment for at risk mental states (Yung et al., 2005) or structured interview for prodromal 
symptoms (Miller et al., 1999) or another recognised diagnostic system to identify those at 
risk of developing psychosis, or ii) people described as recently experiencing a first episode of 
14 
 
psychosis (based on standardised clinical assessment or a recognised diagnostic system to 
identify a nonaffective psychosis diagnosis for retrospective studies), or iii) people with 
nonaffective psychosis (based on standardised clinical assessment or diagnosis). Studies were 
also required to assess i) the prevalence of insomnia disorder or ii) symptoms of insomnia, or 
iii) assess the relationship between insomnia and psychosis symptomatology, in their sample. 
Insomnia should be defined using self-report questionnaires, clinical assessment, semi-
structured interview, or any other standard clinical diagnostic technique. Insomnia should not 
be defined by items within a measure of another construct (e.g. using items within depression 
measures). Where included studies assessed the relationship between insomnia and 
psychosis symptomatology, validated measures of psychosis symptomatology must be used. 
Psychosis symptoms must not be defined solely by items within a measure of another 
condition. 
1.3.2.2. Exclusion Criteria 
Book chapters, case studies, reviews, systematic reviews, commentary, opinion papers, 
theses and conference proceedings were excluded. Studies with samples predominantly 
(>50%) composed of participants where the primary cause of psychosis symptomatology was 
organic (e.g. brain injury, illness, dementia) or with affective psychosis diagnoses (e.g. bipolar 
disorder, postpartum psychosis) were excluded. Studies examining psychotic-like experiences 
in non-clinical participants were excluded. 
 
1.3.3. Data Extraction 
A study-specific proforma was created and piloted (Appendix 1.4.). Study authors, year, title, 
journal, volume (issue), country in which the study was undertaken, study design, and sample 
size was extracted. Demographic data (age, gender or sex, ethnicity or race, diagnosis 
(diagnostic method), and participant setting (inpatient, outpatient, first episode) were 
collated where available. The primary outcome was the assessed prevalence of insomnia 
(disorder or symptoms). This was defined as the percentage of sample participants with 
insomnia at the time point the research was conducted. We collated data on methods of 
assessing insomnia and psychosis symptomatology. If available, we collected information on 
assessed relationships between insomnia and psychosis symptomatology.  
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1.3.4. Quality Appraisal  
The quality of papers selected for review was appraised using i) the Joanna Briggs Institute 
(JBI) Checklist for Prevalence Studies (Munn et al., 2015; Appendix 1.5.) if their primary aim 
was to estimate prevalence (n=10) and/or ii) JBI Checklist for Analytical Cross-Sectional 
Studies (Aromataris, 2020; Appendix 1.6.) if they were cross sectional in design (n=16). 
Authors FR and HL co-rated a sub-selection of five papers, to calibrate quality appraisal. FR 
and HL then separately rated five papers to establish inter-rater reliability, with an initial 
agreement of κ=0.78 for prevalence papers and complete agreement for cross-sectional 
studies. Following discussion, complete agreement was reached. FR rated the remaining eight 
papers alone. Studies were not removed based on their quality rating, however quality was 
considered in narrative synthesis and statistically weighted in quality-effects meta-analysis. 
JBI Checklist outcomes were transformed into a score from 0-1 for use in quality-effects meta-
analyses. This was calculated as 1 point for each ‘yes’ answer and 0 for each ‘no’ or ‘unknown’ 
answer, divided by the number of items in the checklist (see Appendices 1.7. and 1.8.). Where 
possible, Checklist for Prevalence Studies ratings were used in meta-analysis. 
 
1.3.5. Analysis 
Our primary aim was to present a meta-analysis of the prevalence of insomnia in nonaffective 
psychosis. We summarise the estimated prevalence of insomnia in nonaffective psychosis 
overall, in relation to how insomnia was assessed, and by subgroups. Meta-analysis was 
carried out using MetaXL version 5.3. (Barendregt et al., 2013; EpiGear International, Sunrise 
Beach, Queensland, Australia; 2016) an open-access software implemented in Microsoft 
Office Excel. We used fixed, random and quality-effects meta-analyses with double arcsine 
transformation to estimate the pooled prevalence of insomnia disorder or symptoms across 
i) those ten studies where the primary aim was to establish the prevalence of insomnia, ii) all 
fifteen studies reporting an estimated prevalence of insomnia, and iii) in those studies using 
the Insomnia Severity Index (Morin et al., 2011) to estimate the prevalence of insomnia.  The 
use of a quality effects model allows the weighting of studies to be adjusted by their 
methodological quality, assigning lower weight to studies of lower quality, thus reducing a 
primary source of heterogeneity (variance in method between studies; Doi and Thalib, 2008). 
Double arcsine transformation acts to stabilise the variance between estimated prevalence 
statistics (Barendregt et al., 2013). Cochran Q test and I2 were used to assess heterogeneity 
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among studies. Pooled prevalence estimates are reported using 95% confidence intervals 
(CIs). These are back-transformed to percentages for ease of interpretation.  
Our secondary aim was to describe the reported relationships between insomnia symptoms 






Database searches yielded 17,123 results (Figure 1). 6,902 duplicates were removed, leaving 
10,221 records. 54 records passing title and abstract screening were full-text reviewed. 30 
were added to full-text review through hand searching of references, resulting in full-text 
review of 84 papers. These were compared against eligibility criteria and reasons for exclusion 
were recorded. Eighteen papers investigating insomnia in the context of nonaffective 
psychosis were identified for inclusion (Table 1). 
 
Figure 1. PRISMA Flow Chart 
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1.4.1. Study Characteristics 
Included studies reported data for 7,524 participants, of which 6,160 were individuals with 
psychosis (n=29–1802; % of sample 9.1%-100%). Studies represented independent cohorts 
(n=18). Studies were undertaken in: China (n=3), China and Hong Kong (n=1), Hong Kong 
(n=1), England (n=4), the USA (n=3), Singapore (n=2), Germany (online), India, Nigeria and 
Spain. Most were descriptive or analytical cross-sectional in design (Table 1). Included 
descriptive studies describe the prevalence of insomnia in studied populations, whilst 
included analytical studies examine cause and effect relationships between insomnia and 
other symptomatology and may also describe the sample prevalence of insomnia. Study 
design is therefore relevant in considering the primary aim of included studies. 
Table 1. Characteristics of studies included in systematic review.  
Study Country Sample n  
(% of overall) 
Design 
Batalla-Martin et al. (2020) Spain 267 Analytical cross-sectional 
Freeman et al. (2009) England (UK) 30 (9.1%) Analytical cross-sectional 
Freeman et al. (2019) England (UK) 1802 Descriptive cross-sectional 
Grezellschak et al. (2017) Germany (online) 46 (13.7%) Analytical cross-sectional 
Hou et al. (2017) China 623 Analytical cross-sectional 
Li et al. (2016) Hong Kong 388 Analytical cross-sectional 
Li et al. (2017) China 612 Analytical cross-sectional 
Miller et al. (2019) USA 108 Analytical cross-sectional 
Miller et al. (2020) China 328 Analytical cross-sectional 
Miller et al. (2021) USA 598 Analytical cross-sectional 
Mondal et al. (2018) India 124 (24.8%) Descriptive cross-sectional 
Ogbolu et al. (2012) Nigeria 66 (35.9%) Descriptive cross-sectional 
Palmese et al. (2011) USA 175 Analytical cross-sectional 
Reeve et al. (2018) England (UK) 29 Longitudinal observational 
Reeve et al. (2019) England (UK) 60 Analytical cross-sectional 
Seow et al. (2018) Singapore 120 (30%) Descriptive cross-sectional 
Subramaniam et al. (2018) Singapore 279 Analytical cross-sectional 
Xiang et al. (2009) China & Hong Kong 505 Analytical cross-sectional 
Sample n reflects the number of people with nonaffective psychosis in the sample. Where studies include 
participants without nonaffective psychosis, the n(%) of the sample with nonaffective psychosis is provided. 
 
1.4.2. Sample Characteristics 
Thirteen studies sampled only people with a nonaffective psychotic disorder, whilst five 
studies included other populations. Of those five studies which included other populations, 
three estimated the prevalence of insomnia across psychiatric diagnoses (Mondal et al., 2018, 
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Ogbolu et al., 2012, Seow et al., 2018) and two included non-clinical populations (Freeman et 
al., 2009, Grezellschak et al., 2017).  
We were able to extract age and gender or sex demographics for most included studies (Table 
2). Mean age ranged from 23.6 to 50.4yrs. Studies recruiting primarily or exclusively from 
early intervention services had a lower mean participant age (Reeve et al., 2018, Reeve et al., 
2019b, Subramaniam et al., 2018). The percentage of male participants ranged from 34.8 to 
75.2%. Eight studies provided data regarding ethnicity or race for nonaffective psychosis 
participants. Of these, demographics varied depending on where the study was undertaken. 
Specific diagnosis was provided in fifteen studies and schizophrenia was the most common 
diagnosis. Most samples were composed of adult outpatients receiving care in the 
community. One study recruited exclusively from inpatient services (Miller et al., 2020). Two 
other studies recruited from inpatient services and other settings (Freeman et al., 2019, Miller 
et al., 2019). 
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1.4.3. Measuring Insomnia 
Ten studies reported that their primary aim was to estimate the prevalence of insomnia. 
However, fifteen papers reported a prevalence statistic for insomnia in nonaffective psychosis 
populations (Table 3).  
There was significant variation in the measures used to estimate the prevalence of insomnia 
disorder or symptoms of insomnia. Five studies reported that insomnia was established using 
bespoke interview or question sets (Hou et al., 2017, Li et al., 2016b, Li et al., 2017, Miller et 
al., 2021, Xiang et al., 2009), with two studies (Li et al., 2017, Xiang et al., 2009) specifying 
that these were based on DSM-IV criteria for insomnia disorder (American Psychiatric 
Association, 1980).  
Table 3. The prevalence of insomnia in nonaffective psychosis populations.  
 Feature Severity 
Study Insomnia 
Measure 
Prev. DIS DMS EMA Mild Mod Severe 
Batalla-Martin 
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   38.7%⁺ 23.7%⁺ 4.3%⁺ 
Ogbolu et al. 
(2012) 
Sleep-50 10.6%       
Palmese et al. 
(2011) 
ISI (>15) 48%    35%+ 35%⁺ 13%⁺ 
Reeve et al. 
(2019) 
DISP 
Sleep diaries & 
actigraphy 
ISI 
















Seow et al. 
(2018) 
BIQ 25.0% 28.3% 18.3% 6.7%    
Subramaniam 
et al. (2018) 
ISI (>15) 22.6%    39.1%⁺ 22.6%⁺ 




36.0% 21.2% 23.6% 11.9%    
Those in grey aimed to establish insomnia prevalence. Prev. = Prevalence. *Indicates prevalence 
statistics created by summarising ISI severity, + indicates ISI score categories. Features comprise 
delayed initiation of sleep (DIS), disrupted sleep maintenance (DMS) and early morning awakening 
(EMA). 
Seven studies used the Insomnia Severity Index (ISI; Bastien et al., 2001). The ISI is based on 
DSM-IV insomnia disorder (American Psychiatric Association, 1980) and aims to assess the 
symptoms of insomnia disorder during the prior two weeks (delayed sleep initiation (DIS), 
disrupted sleep maintenance (DMS), early morning wakening (EMA)), functional impairment, 
and related distress. ISI score brackets indicate no clinically significant insomnia (<7), 
subthreshold (8-14), moderate (15-21), or severe (22-28) clinical insomnia. Although the ISI 
was designed to measure change in insomnia symptoms, an ISI cut off of 10 has been 
suggested to be optimal for identifying insomnia in community samples (Morin et al., 2011). 
Included studies used a variety of cut-off scores to identify any insomnia (score >7; Miller et 
al., 2020) to moderate or severe insomnia (score >15; Palmese et al., 2011, Subramaniam et 
al., 2018).  
Three studies reported a prevalence based or partially based on the Sleep-50 (Spoormaker et 
al., 2005). The Sleep-50 was developed based on the DSM-IV. The insomnia subscale assesses 
some symptoms of insomnia (DIS, DMS), sleep length, and worries affecting sleep over the 
previous month. One study used the Brief Insomnia Questionnaire (BIQ; Kessler et al., 2010). 
This is based on DSM-IV, ICD-10 (World Health Organization, 1994), Research Diagnostic 
criteria (Edinger et al., 2004), and International Classification of Sleep Disorders-2 criteria 
(American Academy of Sleep Medicine, 2005); specifically assessing DIS, DMS, EMA, sleep 
quality, daytime functional impairment and associated distress over the previous month. One 
study used the Oveido Sleep Questionnaire (OSQ; Bobes et al., 1998), which measures DSM-
IV and ICD-10 insomnia disorder; specifically assessing DIS, DMS, EMA, sleep quality, daytime 
functional impairment and associated distress over the previous month.  
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Four studies reported prevalence statistics based on more than one criterion. Batalla-Martin 
et al. (2020) reported prevalence statistics based upon i) reporting of any insomnia symptom, 
ii) the ISI (>10), iii) the OSQ using ICD-10 criteria and iv) the OSQ using DSM-IV criteria for 
insomnia disorder. Freeman et al. (2009) reported prevalence statistics based on the i) ISI 
(score >10) and ii) Sleep-50. Mondal et al. (2018) reported prevalence statistics based on i) 
the ISI (>10) and ii) using screening questions based on Harding (2004; cited in Mondal et al., 
2018). Reeve et al. (2019b) specified a single prevalence of insomnia in early psychosis using 
a testing process composed of the Diagnostic Interview for Sleep Disorders (Merikangas et 
al., 2014), consensus sleep diaries, and actigraphy. They additionally used the Sleep-50 in a 
subset of participants (29/60 participants; 48.3%). 
 
1.4.4. Measuring Psychosis Symptomatology 
Ten studies examined the relationship between psychosis symptomatology and insomnia. 
Psychosis symptomatology was assessed using a variety of measures (Table 4). Four studies 
used the Positive and Negative Symptom Scale (PANSS; Kay et al., 1987). Two studies used 
the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1988). One study used the Green 
et al. Paranoid Thoughts Scale – B (R-GPTS-B; Freeman et al., 2021) and the Cardiff Anomalous 
Perceptions Scale (CAPS; Bell et al., 2006). One study used the Paranoia Checklist (PC; Schlier 
et al., 2016). One study used the Clinical Global Impression Scale - Schizophrenia Version (CGI-
S; Haro et al., 2003). Lastly, one study used the Specific Psychotic Experiences Questionnaire 
(SPEQ; Ronald et al., 2014). 
 
1.4.5. Study Quality  
The quality of included studies primarily assessing prevalence (n=10) was variable (see 
Appendix 1.7.). Included studies of prevalence typically used an appropriate sample frame to 
address their aim, provided a thorough description of the study setting and of included 
participants, and had sufficient coverage of data. Several studies failed to characterise the 
method of assessing insomnia in adequate detail to appraise their approach or 
standardisation. Studies typically did not sample from the underlying population in a 
representative manner or did not report how sampling was undertaken. They often did not 
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report the number of approached persons who chose not to participate (response rate). Only 
one study presented a statistical confidence interval around their estimated prevalence of 
insomnia. 
The quality of included cross-sectional studies (n=16) was good (see Appendix 1.8.). Most 
studies reported inclusion and exclusion criteria, described their setting and participant 
characteristics well, and used appropriate definitions of diagnosis and of their outcome 
measure. Several studies did not address confounds in their dataset and did not incorporate 
strategies to manage confounds in analysis. 
1.4.6. Outcomes of Interest 
1.4.6.1. Prevalence of Insomnia 
Fifteen papers reported one or more prevalence statistic for insomnia (Table 3). The 
measured prevalence of insomnia/insomnia symptoms ranged from 7.9% to 75% (Batalla-
Martin et al., 2020, Mondal et al., 2018). The prevalence of insomnia varied with the 
subpopulation measured. Those studies which assessed first episode or early psychosis 
populations report a prevalence of insomnia symptoms of 39.1 to 50% (Reeve et al., 2019b, 
Subramaniam et al., 2018). Those which examined community outpatients report a 
prevalence of 7.9% to 75%. Miller et al. (2020) reported a prevalence of 17.7% for an inpatient 
group.  
A group of studies used a bespoke set of questions, based on DSM-IV criteria for insomnia 
disorder. These provided prevalence statistics between 19 and 45%. For those prevalence 
statistics measured using a validated questionnaire (e.g. ISI. BIQ, Sleep-50), the estimated 
prevalence was 10.6 – 83%. Estimated prevalence based on scoring on or above ISI 
‘subthreshold’ insomnia (ISI score >7) was 17.7% in one study. Several studies based their 
prevalence estimate on scoring on or above ISI ‘mild’ insomnia (ISI score >10), giving 
estimations of 41.2 to 50%. Others based their overall estimate on scoring on or above 
‘moderate clinical insomnia’ (ISI score >15), giving an estimated prevalence of 22.6 to 48%. 
Several studies included prevalence rates for each ISI severity category. These studies 
reported subthreshold or mild insomnia (ISI score >7) for 3.3 to 39.1%, moderate clinical 
insomnia (>15) for 10.5 to 35%, and severe clinical insomnia (>21) for 3 to 28.3%. Three 
studies using the Sleep-50 produced prevalence statistics of 10.6 to 60%. The BIQ gave an 
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estimated prevalence of 25% in an early intervention population. The OSQ based on DSM-IV 
criteria gave a prevalence of 7.9% and on ICD-10 criteria, 23.2% in the same sample. 
Four studies reported prevalence based on more than one criterion. Batalla-Martin et al. 
(2020) report a prevalence of between 7.9% based on the OSQ using DSM-IV criteria for 
insomnia disorder, to 63% for any insomnia symptom. Freeman et al. (2009) report a 
prevalence of 60% on the Sleep-50 and 84% on the ISI (score >10). Mondal et al. (2018) report 
a prevalence of 66.7% on the ISI (>10) and 75% based on Harding (2004). One study (Reeve et 
al., 2019b) used a mixed-methods protocol to assess sleep disorders in people experiencing 
psychosis, estimating an insomnia disorder prevalence of 50%.  
Three studies reported the prevalence of elements of insomnia – DIS, DMS, and EMA (Miller 
et al., 2021, Seow et al., 2018, Xiang et al., 2009). These studies had used bespoke clinical 
questionnaires and assessment, or the BIQ to assess insomnia. The reported prevalence of 
DIS was between 20.5% and 28.3%. The reported prevalence of DMS was between 18.3% and 
23.6%. One study provided a pooled prevalence for DIS and DMS of 45% (Miller et al., 2021). 
The reported prevalence of EMA was between 6.7% and 27%. 
 
1.4.6.2. Meta-Analyses 
Pooled estimates of prevalence were calculated for i) those ten studies for which a primary 
aim was to determine the prevalence of insomnia ii) all fifteen studies which reported a 
prevalence of insomnia and iii) those seven studies which used the ISI to establish insomnia 
prevalence. For additional tables and figures, see Appendix 1.9.  
Across those studies aiming to establish prevalence, the random-effects pooled prevalence of 
insomnia disorder or symptoms in nonaffective psychosis was 36.5% (95% CI=27.2–46.4%; 
Figure 2). The quality-effects pooled prevalence was 32.3% (95% CI=20.9–45%). The fixed-
effects pooled prevalence was 32.9% (95% CI=31–34.9%). There was significant heterogeneity 
and variability across studies (I2 = 95.1%, 95% CI=92.7-96.7%). Publication bias was assessed 
using a funnel plot (Appendix 1.9.1.). Measured prevalence statistics were highly variable and 





Figure 2. Random-effects forest plot for studies aiming to establish prevalence 
Across all studies reporting prevalence, the random-effects pooled prevalence was 34.8% 
(95% CI=27.4–42.6%; Figure 3). The quality-effects pooled prevalence was 35.5% (95% CI=26–
45.6%). The fixed-effects pooled prevalence was 36.9% (95% CI=35.6–38.1%). There was 
significant heterogeneity and variability (I2 = 97.1%, 95% CI=96.2–97.8%). As this analysis 
included more studies, confidence intervals were narrower than those produced by only 
studies aiming to establish prevalence. Publication bias was assessed using a funnel plot 
(Appendix 1.9.2.). Measured prevalence statistics were highly variable and more extreme 
prevalence estimates were extracted from studies with small or moderate sample sizes. 
 
Figure 3. Random-effects forest plot for all studies reporting prevalence 
Those studies which used the ISI to assess insomnia produced a random-effects pooled 
prevalence of insomnia disorder or symptoms of 45.6% (95% CI=32–59.6%; Figure 4). The 
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quality-effects pooled prevalence was 42.5% (95% CI=23.6–62.5%). The fixed-effects pooled 
prevalence was 43% (95% CI=42–45.5%). There was significant heterogeneity and variability 
(I2 = 97.6%, 95%CI=96.4–98.3%). These pooled prevalence estimates are higher than those 
reported for studies aiming to establish prevalence or reporting prevalence statistics. The 
confidence intervals arising from this analysis were wider, suggesting that these results may 
be less reliable. This is partially due to fewer studies contributing to the estimate. Publication 
bias was assessed using a funnel plot (Appendix 1.9.3). This suggested that prevalence 
statistics were highly variable and that more extreme estimates were extracted from studies 
with smaller sample sizes. 
 
Figure 4. Random-effects forest plot for studies using the ISI 
 
1.4.7. Insomnia and Symptomatology   
1.4.7.1. Insomnia and Psychosis Symptomatology   
Ten papers investigated the relationship between insomnia and psychosis symptomatology 
(Table 4). Most studies used ISI scores as a continuous variable in analysis (Freeman et al., 
2019, Grezellschak et al., 2017, Miller et al., 2020, Miller et al., 2019, Palmese et al., 2011, 
Reeve et al., 2018, Subramaniam et al., 2018). The remaining three studies split their sample 
into those with or without insomnia, conducting between-group analyses (Hou et al., 2017, 
Miller et al., 2021, Xiang et al., 2009). 
Two studies identified a significant positive relationship between insomnia severity on the ISI 
and PANSS total, positive symptom, and general scores (ρ=0.33, p=0.001; ρ=0.37, p<0.001; 
ρ=0.42, p<0.001, Miller et al. (2019); ρ=0.18, p<0.002; ρ=0.19, p<0.002; ρ=0.17, p<0.002, 
Miller et al. (2020)). Miller et al. (2021) demonstrated a correlation between early morning 
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awakening (as a yes/no categorical variable) and PANSS total, positive, and general scores 
(bivariate Spearman’s rho ρ=0.11, p<0.001; ρ=0.1, p<0.001; ρ=0.13, p<0.001) but did not find 
a relationship between disrupted sleep initiation or maintenance and PANSS scores. In linear 
regression, controlling for confounding factors, early morning awakening was still associated 
with PANSS total, positive and general scores (β=0.12, p<0.001; β=0.11, p<0.001; β=0.14, 
p<0.001). In contrast, Subramaniam et al. (2018) found no relationship between ISI and PANSS 
scores in first episode of psychosis. Palmese et al. (2011) did not find a relationship between 
insomnia severity and CGI-S positive, negative or cognitive scores. 






Freeman et al., 2019 ISI GPTS-B 
CAPS 
Insomnia severity positively correlated with 
paranoia, hallucinations. 
Grezellschak et al., 2017 ISI PC Insomnia severity positively correlated with 
paranoia; in a direct, total and indirect 
manner. 
Hou et al., 2017 Bespoke 
questionnaire 
BPRS Insomnia presence related to more severe 
positive, negative, and anxiety symptoms. 
Miller et al., 2019 ISI PANSS Insomnia severity significantly related to 
total positive, and general symptoms. 
Miller et al., 2020 ISI PANSS Insomnia severity significantly related to 
total positive, and general symptoms. 
Miller et al., 2021 Bespoke 
questionnaire 
PANSS EMA was associated with higher total, 
positive general symptoms. 
Palmese et al., 2011 ISI CGIS-S Insomnia severity significantly associated 
with depressive and global symptoms. 
Reeve et al., 2018 ISI SPEQ Insomnia predicts paranoia and 
hallucinations within and across time. 
This is mediated by depression and anxiety. 
Subramaniam et al., 2018 ISI PANSS Insomnia severity not associated with 
positive, negative, or global symptom scores. 
Xiang et al., 2009 Bespoke 
questionnaire 
BPRS Insomnia associated with severity of positive 
and anxiety symptoms.  
 
Two studies using the BPRS found participants with insomnia had more severe positive and 
anxiety symptoms (Hou et al., 2017, Xiang et al., 2009). Hou et al. (2017) found that positive, 
negative and anxiety symptoms were more severe in the insomnia group (T/Z=5.4, p<0.001; 
T/Z=-4.7, p<0.001; T/Z=-6.1, p<0.001). Xiang et al. (2009) demonstrated that positive and 
anxiety symptoms were more severe in the insomnia group (T/Z=-5.3, p<0.001; T/Z=5.8, 
p<0.001), but negative symptoms were not. 
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Three studies examined a relationship between insomnia and paranoia or persecutory 
thoughts in people with nonaffective psychosis. Grezellschak et al. (2017) demonstrated that 
ISI scores are correlated with paranoia (ρ=0.47, p<0.01), insomnia has a direct effect on 
paranoia and that this is mediated by emotion regulation (t=2.18, 95% CI 0.55-1.99, 
effect=0.76, p=0.04). Freeman et al. (2019) found that ISI scores were significantly correlated 
with paranoia and with hallucinations (r=0.41, p<0.001; r=0.39, p<0.001). One other study 
found that insomnia was a significant predictor of paranoia and hallucinations within and 
across time (Reeve et al., 2018). These statistical relationships were mediated by depression 
and anxiety symptoms.  
1.4.7.2. Insomnia, Psychotic Symptomatology and Mood 
Whilst mood was not a focus of the review, several included studies assessed the relationship 
between insomnia and mood. Miller et al. (2021) found that EMA was significantly correlated 
with Calgary Depression Rating Scale for Schizophrenia total scores (CDSS; Addington et al., 
1990; ρ=0.46, p<0.001). Hou et al. (2017) found that Montgomery–Åsberg depression rating 
scale scores were poorer in those with insomnia (Müller et al., 2003; T/Z=-8.4, p<0.001). Xiang 
et al. (2009) found that Hamilton Depression Scale scores were greater in those with insomnia 
(Hamilton, 1960; T/Z=-13, p<0.001). Palmese et al. (2011) found that insomnia severity was 
related to CGI-S depression scores and CDSS scores (F(3,109)=3.99, p=0.01; F(3,170)=9.03, 
p<0.001). As above, Reeve et al. (2018) found that anxiety and depression were significant 
mediators in the relationship between insomnia and paranoia or hallucinations, within and 
across time. 
 
1.4.7.3. Insomnia, Psychotic Symptomatology and Suicidality 
Four included studies examined the relationship between insomnia, psychosis 
symptomatology and suicidality (Li et al., 2016b, Miller et al., 2020, Miller et al., 2021, Miller 
et al., 2019). Miller et al. (2019) found that ISI scores were positively correlated with Beck 
Scale for Suicidal Ideation scores (BSSI; Beck et al., 1979; ρ=0.29, p=0.002). These remained 
significantly related to suicidal ideation in linear regression analysis controlling for confounds 
(including PANSS total; OR=1.14, 95% CI 1.01-1.28, p=0.029). BSSI scores also significantly 
varied across ISI categories. In logistic regression analysis controlling for confounding factors 
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(including PANSS total); ISI scores were significantly associated with a lifetime history of 
suicide attempt (OR=1.1, 95% CI 1.03-1.19, p=0.008). Insomnia was further associated with 
15-fold increase in lifetime suicide attempt (OR=14.8, 95% CI 1.4-157, p=0.025).  
Miller et al. (2020) found that participants reporting suicidal ideation (on the CDSS) had higher 
ISI total scores (p=0.03). The prevalence of insomnia was greater in those experiencing 
suicidal ideation (χ²=9.39, p=0.02). Logistic regression, controlling for confounding factors, 
found that ISI score remained related to the presence of suicidal ideation (OR=0.10, 95% CI 
1.02-1.19, p=0.017). However, they suggest that this relationship was caused by depressive 
symptomatology (related to both insomnia and suicidal ideation).  In logistic regression 
analysis, insomnia was also associated with increased odds of lifetime suicide attempt 
(OR=1.07, 95%CI 1-1.13, p=0.046) and with a 2.5-fold increase in current suicidal ideation 
(OR=2.56, 95% CI 1.1-5.92, p=0.029).  
Miller et al. (2021) studied suicidality and insomnia components. They identified that the 
prevalence of suicidal ideation was related to EMA (categorical variable; χ²=5, p=0.03). 
Logistic regression, controlling for confounding factors, found that DIS and DMS were not 
significantly related to suicidal ideation. However, participants with DIS and DMS were more 
likely to have attempted to end their life by suicide in the last 6 months (χ²=9.4, p=0.004). 
There was no relationship between EMA and recent attempt to end one’s life. In logistic 
regression, controlling for confounds, DIS and DMS increased the risk of attempt to end one’s 
own life by 5.5 fold (OR=5.5, 95% CI 1.4-21.2, p=0.013) but EMA did not.  
Lastly, Li et al. (2016b) found a higher prevalence of suicide attempt in participants with 
insomnia at baseline (statistics not provided). Insomnia was also related to a higher likelihood 
of attempt to end one’s life over the follow-up period (Hazard Ratio=4.63, 95% CI 1.4-15.36, 
p<0.05), after controlling for confounds. 
 
1.4.7.4. Insomnia, Psychotic Symptomatology and Quality of Life 
Several included studies examined quality of life. Batalla-Martin et al. (2020) assessed the 
relationship between the presence of insomnia and quality of life on the EuroQol (The 
EuroQol Group, 1990). Logistic regression demonstrated that the presence of insomnia was 
significantly related to poorer mobility (OR=3.54, 95% CI 1.88-6.65, p<0.001), self-care 
32 
 
(OR=2.69, 95% CI 1.36-5.32, p 0.004), activity (OR=3.56, 95% CI 1.97-6.44, p<0.001), 
pain/discomfort (OR=4.29, 95% CI 2.37-7.74, p<0.001), and anxiety/depression (OR=3.01, 
95% CI 1.61-6.65, p=0.001) scores.  
Subramaniam et al. (2018) demonstrated a relationship between ISI and WHOQOL (WHOQOL 
Group, 1994) scores in participants experiencing a first episode of psychosis. In multiple linear 
regression, controlling for confounding variables, higher ISI score was significantly related to 
poorer WHOQOL physical (β=-3.20, 95% CI -3.95-2.44, p<0.001), psychological (β=-2.46, 95% 
CI -3.45-1.48, p<0.001), social relationships (β=-3.06, 95% CI -4.01-2.12, p<0.001), and 
environment (β=-1.64, 95% CI -2.5-0.78, p<0.001) scores.  
Hou et al. (2017) used the Short Form Health Survey (SF12; Ware Jr et al., 1996), 
demonstrating that SF12 mental scores were poorer in those with insomnia (T/Z=3.9, 
p<0.001). Using multiple linear regression, Li et al. (2017) found SF12 physical and mental 
scores were poorer in participants with insomnia (β=-1.96, p=0.01; β=-3.17, p<0.001). Xiang 
et al. (2009) demonstrated that WHOQOL physical (T/Z=-10.1, p<0.001), psychological (T/Z=-
7.7, p<0.001), social relationships (T/Z= -5.9, p<0.001), and environment (T/Z=-4.9, p<0.001) 
scores were poorer for those with insomnia. When ANCOVA was used to control for 
confounding factors, those with insomnia still achieved poorer scores in the physical 
WHOQOL domain (F=6.6, p=0.01).  
Palmese et al. (2011) found that insomnia severity (categorical) was related to Quality of Life 
Enjoyment and Satisfaction Questionnaire total scores (Ritsner et al., 2005; F(3,169)=8.52, 
p<0.001). Lower QOL was related to depression scores on the CDSS as well as insomnia 




1.5. Discussion  
We aimed to establish the prevalence of insomnia disorder or symptoms in people with 
nonaffective psychosis. As a secondary outcome, we characterise the relationship between 
insomnia and psychosis symptomology.  
 
1.5.1. The Prevalence of Insomnia in Nonaffective Psychosis 
Our results suggest that insomnia is prevalent in nonaffective psychosis, with an estimated 
pooled prevalence of 32.3% quality-effects and 36.5% random-effects across studies primarily 
aiming to establish prevalence, 35.5% quality-effects and 34.8% random-effects across all 
studies reporting prevalence, and 42.5% quality-effects and 45.6% random-effects in studies 
using the ISI to assess prevalence.  
Across meta-analytic models, resulting pooled prevalence and estimated 95% confidence 
intervals varied. Fixed-effects models produced the narrowest confidence intervals, as they 
estimate only variance within studies and assume they are measuring a single underlying 
statistic (Tufanaru et al., 2015). They also lend the highest weighting to those studies with the 
largest samples. Where between-study heterogeneity is present, fixed-effects analyses 
greatly underestimate the variability in the resulting pooled prevalence (Brockwell and 
Gordon, 2001). Given the significant variability evidenced by I2 and Q statistics in our analyses, 
fixed-effects models are not appropriate. Random-effects models produce wider confidence 
intervals as they estimate variance both within and between studies, and assume they are 
measuring an underlying statistic which differs between studies (Tufanaru et al., 2015).  
Quality-effects models statistically estimate between-study variability weighted by study 
quality; therefore, the resulting confidence intervals depend partially on the appraised quality 
of included studies. They introduce another source of variance – the quality of the research 
undertaken. Whilst quality varied, assessed quality of reviewed studies was slightly lower in 
those reporting the highest prevalence of insomnia. Therefore, the resulting quality effects 
models typically provide a lower pooled prevalence than random-effects model results. 
However, most assessed quality ratings were moderate to high. Random-effects models can 
exacerbate bias in the resulting pooled prevalence when large study results differ from 
smaller study results, and when this difference is due to variability in the quality of studies 
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(Doi and Thalib, 2008). When a higher number of studies are included, confidence intervals 
narrow. As expected, the confidence intervals were narrowest when all studies reporting 
prevalence statistics are included and widest when only studies using the ISI are included.  
It is not possible to directly compare the results of presented meta-analyses. The studies 
contributing to the pooled prevalence overlap between analyses (e.g. the n=7 studies using 
the ISI are included in the n=15 studies reporting a prevalence estimate). Studies using the ISI 
descriptively produce a higher pooled prevalence estimate for insomnia than both other 
prevalence estimates. This may suggest that use of the ISI overestimates insomnia 
prevalence. Importantly, these studies use different cut-off scores on the ISI to identify 
insomnia (from >7 to >15), and some of these studies use a lower cut-off to indicate insomnia 
than recommended (Morin et al., 2011). Future assessment of insomnia should use 
recommended cut-off values to identify clinically significant insomnia. Single prevalence 
statistics from included studies were extremely variable - between 7.9% and 75% across 
studies and methodologies. This resulted in relatively wide confidence intervals around 
pooled prevalence estimates.  
The pooled insomnia prevalence statistics were above those estimates found in the general 
population (10-30%; Ohayon, 2002, Roth, 2007). Ohayon (2002) note that general population 
prevalence is highest for insomnia symptoms (approx. 30%) and lowest for insomnia disorder 
(approx. 6%).  Morin et al. (2006) found that 29.9% of the general population present with 
one or more insomnia symptom and 9.5% meet criteria for DSM-V insomnia. Some studies 
included in our review estimate a much higher prevalence. Similarly, we found that those 
studies using strict DSM-IV or ICD-10 criteria produced the lowest prevalence estimates 
(7.9%), although most other included studies used validated measures based on DSM criteria. 
In research and clinical practice, valid and standardised definitions and assessment of 
insomnia symptoms or Insomnia Disorder should be used.    
In the general population, western countries report higher prevalence of insomnia than Asian 
countries (Cao et al., 2017). The pooled prevalence of insomnia in China has been estimated 
as 15% (Cao et al., 2017), whilst the prevalence of insomnia in the USA and Europe is 
estimated as ~30% (Roth, 2007). The selected studies reviewed in this work originate in both 
Asian and western countries. Studies undertaken in China or Hong Kong (Hou et al., 2017, Li 
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et al., 2016b, Li et al., 2017, Miller et al., 2021) and Nigeria (Ogbolu et al., 2012) produced 
lower prevalence estimates than those undertaken in the western world. There is some 
evidence that insomnia may vary by ethnicity and socioeconomic status (Whinnery et al., 
2014) and that severity is related to minority ethnicity and experiences of racial discrimination 
(Cheng et al., 2020). Most included studies described the race or ethnicity of their 
participants. However, prevalence data were not presented by ethnicity therefore these 
effects could not be studied. Clinicians working with people affected by psychosis should be 
aware that insomnia is likely prevalent in their population, particularly given the higher 
proportion of people of minority ethnicity.  
Insomnia symptoms increase with age in the general population (Ohayon, 2002, Roth, 2007). 
Delayed sleep initiation is also more prevalent in adolescents and young adults (Kocevska et 
al., 2021). Participants sampled in our review were relatively homogenous in age and 
prevalence estimates found in first episode populations did not descriptively differ from those 
examining older participants. Insomnia prevalence is higher in women in the general 
population (Zeng et al., 2020, Zhang and Wing, 2006). Most studies included in our systematic 
review recruited more men (34.8 to 75.2% male), as is typical for populations of people with 
nonaffective psychosis (Aleman et al., 2003).  
Only one included study provided a breakdown of prevalence estimate by diagnosis within 
nonaffective psychosis diagnoses (Li et al., 2016b). However, there were not sufficient 
participants in each category to draw any conclusions.   
No included study examined insomnia prevalence in prodromal groups. Only three studies 
examined insomnia prevalence in first episode psychosis groups, limiting the conclusions that 
can be drawn about the prevalence of insomnia in different nonaffective psychosis 
subpopulations. Work to establish the prevalence of sleep disorders and insomnia specifically 
in these subgroups would be of use. Compared to nonaffective psychosis, the estimated 
prevalence of insomnia in bipolar disorder is ~40% (Laskemoen et al., 2019, Steinan et al., 
2016) and in depression ~80% (Ohayon, 2002, Ohayon et al., 2000). It is difficult to directly 
compare estimated prevalence statistics between diagnostic groups due to large 




A small subset of studies deconstructed insomnia into associated features (difficulty initiating 
sleep, maintaining sleep, early morning wakening). As with overall prevalence estimates, 
these results were very variable but higher than those in the general population (Morin et al., 
2006). Cohrs (2008) suggest that up to 80% of people with schizophrenia experience at least 
one symptom of insomnia. Polysomnographic work in nonaffective psychosis has identified 
that longer sleep onset latency, increased wake time after sleep onset and earlier wakening 
are common (Chan et al., 2017, Chouinard et al., 2004), all of which are features of insomnia. 
Actigraphy work has also identified features of insomnia including longer sleep onset latency 
and more fragmented sleep in schizophrenia (Wee et al., 2019). Additionally, overall time 
asleep, sleep efficiency, REM sleep and slow wave sleep are atypical in nonaffective psychosis 
(Chouinard et al., 2004, Reeve et al., 2015) and there is evidence that overarching circadian 
rhythms are affected (Monti et al., 2013). In addition to insomnia, the prevalence of sleep 
apnoea (Sharafkhaneh et al., 2005), hypersomnia (Hawley, 2006, Hawley et al., 2010) and 
nightmare disorder (Reeve et al., 2019b, Sheaves et al., 2015) are increased in nonaffective 
psychosis.  
No included study examined insomnia symptoms across time. Previous research has 
suggested that sleep disturbance predicts the transfer from prodromal to first episode 
psychosis (Ruhrmann et al., 2010). Sleep disorder is prevalent in prodromal psychosis (Tan et 
al., 2001) and is tightly linked to experienced symptomatology across time in this group 
(Lunsford-Avery et al., 2015). Reeve et al. (2019a) found that shorter sleep duration is 
associated with increased symptomatology over time in people experiencing prodromal 
psychosis. The relationship between insomnia and psychosis symptoms are thought to be 
bidirectional in schizophrenia (Cosgrave et al., 2018). Longitudinal work examining the 
relationship between sleep disorder, emergent symptomatology, symptom severity and the 
recovery arc would be of great value. 
 
1.5.2. Measuring Insomnia and Psychosis 
Included studies used robust methods of insomnia assessment (including multiple 
measurements), specific questionnaire measurements of insomnia, and/or researcher or 
clinician-designed discrete questions about insomnia. Most included studies used self-report 
measures. This is a common diagnostic approach for insomnia disorder in addition to clinical 
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interview, however some authors suggest that self-report may be less reliable in determining 
sleep features than objective (actigraphy or polysomnography; Vadas et al., 2015). Our 
systematic review did not include identification of insomnia using tools intended to measure 
another construct, such as the Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 1989) or 
Epsworth Sleepiness Scale (Johns, 1991). These measures primarily aim to measure other 
constructs of sleep (quality and daytime somnolence) and do not accurately characterise 
insomnia (Faulkner and Sidey-Gibbons, 2019). Symptoms of psychosis were measured using 
validated questionnaires including the PANSS, BPRS, GPTS, CAPS, SPEQ, PC and CGIS-S. 
Measurement variability for both insomnia and psychosis symptoms will contribute to 
heterogeneity in pooled prevalence estimates and uncertainty in the relationship between 
insomnia and symptoms.  
 
1.5.3. Insomnia and Psychosis Symptomatology  
 
The quality of cross-sectional analytical studies included was high. Several studies provided 
evidence for a relationship between insomnia severity and overall or positive symptoms, 
including hallucinations and paranoia. The relationship between insomnia and negative 
symptoms was less clear – one study found that those with insomnia had higher negative 
symptoms, whilst others did not. Sleep disorder is related to psychosis-like experience in the 
general population (Barton et al., 2018). In people with psychosis, sleep disorder is associated 
with increased symptomatology; including severity of flattened affect, hallucinations, and 
delusion (Davies et al., 2017, Reeve et al., 2015).  
Several included studies found a relationship between insomnia and anxiety and depression 
subscales within psychosis measures. Others found increased anxiety and low mood in 
participants with higher insomnia symptoms. In the general population, insomnia is 
associated with increased risk of low mood or anxiety (Ford and Kamerow, 1989, Li et al., 
2016a) and the relationship between insomnia and mood disorder is bidirectional (Jansson-
Fröjmark and Lindblom, 2008). Two included studies demonstrated that the relationship 
between insomnia and psychosis symptomatology is mediated by affect or affect regulation 
(Grezellschak et al., 2017, Reeve et al., 2018).  
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Insomnia is associated with increased risk of suicidal ideation and attempt in the general 
population (Russell et al., 2019, Lin et al., 2018). People affected by psychosis are at a higher 
risk of suicide than the general population (Depp et al., 2016). Included studies assessing 
suicide in nonaffective psychosis found that greater insomnia was related to higher suicidal 
ideation and a greater risk of attempting to end one’s own life prior to assessment and by 
follow-up, thus suggesting insomnia increases the vulnerability in an already vulnerable 
population (Li et al., 2016, Miller et al., 2020, Miller et al., 2021, Miller et al., 2019). The 
relationship between insomnia and suicidality in psychosis may be mediated by depressive 
symptomatology (Miller et al., 2020). 
Insomnia is associated with poorer quality of life in non-clinical populations (Kyle et al., 2010). 
Some included studies assessed quality of life, demonstrating that insomnia is related to 
poorer quality of life across domains (mobility, self-care, activity, pain, and anxiety or low 
mood). Research generally indicated that mental-health related quality of life was more 
impacted than physical quality of life. Published works have linked poorer sleep to positive 
symptom severity and poorer quality of life (Afonso et al., 2014).  
 
1.5.4. Treatment for Insomnia 
Cognitive behavioural therapy is effective in treating insomnia (CBTi; Okajima et al., 2011, 
Trauer et al., 2015) and is considered gold-standard treatment (Wilson et al., 2019). It has 
been shown to be more effective than medication (Trauer et al., 2015) and effective in diverse 
mental health populations (Mitchell et al., 2012). Whilst the evidence base for use with people 
experiencing psychosis is in its infancy, initial results suggest that CBTi is effective in reducing 
insomnia and has mixed impacts on psychosis symptomatology (Freeman et al., 2015, Myers 
et al., 2011). Different insomnia symptom profiles are associated with different response to 
CBTi in nonaffective psychosis (Chiu et al., 2018, Waters et al., 2020). Furthermore, people 
with nonaffective psychosis identify sleep disorder as a desirable target for intervention (Chiu 
et al., 2016, Waite et al., 2016) and express preference for CBTi over medication (Waters et 





There are several limitations to the present systematic review and meta-analysis. We included 
only studies published in English. Studies were not excluded by quality, due to the small 
number of studies meeting eligibility criteria. However studies were generally of moderate or 
good quality. The definition and assessment of insomnia disorder or insomnia symptoms was 
diverse, increasing the variance observed in results and limiting conclusions drawn.  Between-
study variations in sample size, design, and quality limit how findings can be interpreted, 
however as described we attempted to correct for this in meta-analysis. It is likely that 
publication bias impacted on the presented results. We did not consider the impact of 
psychoactive medication. Atypical antipsychotic medications have been shown to be related 
to improved sleep in psychosis (Haffmans et al., 2004), and may explain why lower insomnia 
prevalence was found in inpatient populations. No included papers assessed prodromal 
psychosis and few studies examined first episode populations. This meant that no conclusions 
could be drawn about the development of insomnia prevalence with the development of 
psychosis.  
1.6. Conclusions  
Insomnia is prevalent in nonaffective psychosis and is related to more severe positive and 
overall symptomatology, mood difficulties, suicidal ideation or attempt, and reduced quality 
of life. Clinicians working with people experiencing psychosis should be aware of the 
prevalence of insomnia and offer targeted assessment and evidence-based intervention for 
sleep disorder. Furthermore, they should be aware that insomnia is not simply an outcome of 
psychosis symptomatology but a primary disorder which may drive increased psychosis and 
mood symptomatology. Research investigating insomnia prevalence and symptom correlates 
should use standardised definitions of insomnia disorder and insomnia symptoms and 
standardised and validated methods of assessment of insomnia and psychosis 
symptomatology. Further research which explores i) the prevalence of insomnia in prodromal 
and first episode psychosis populations, ii) the relationship between psychosis symptom 
profiles and insomnia disorder or symptoms, and iii) how the presence of insomnia impacts 
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Chapter 2: Implementation of a Digital Cognitive Behavioural Therapy 
Intervention for Insomnia in First Episode Psychosis in the Context of 
Covid19- A Pilot Mixed Methods Study 
 
Prepared in accordance with submission guidelines for Digital Health 




2.1. Plain Language Summary 
 
Background: Covid-19 and regulations negatively affect population mental health and sleep. 
They likely have a bigger impact on people who already have mental health conditions, 
including psychosis. Psychosis means experiencing or believing things that are not real and 
having confused thoughts. Difficulty falling or staying asleep (‘insomnia’) is common in people 
with psychosis, including people experiencing psychosis for the first time (a ‘first episode’). 
People with worse insomnia have worse psychosis symptoms. We know worry makes 
insomnia worse. Due to Covid19, insomnia and worry could worsen and increase psychosis 
symptoms. Cognitive Behavioural Therapy is a psychotherapy that is effective in reducing 
insomnia (CBTi) in people with or without psychosis. CBT for insomnia can be delivered 
digitally (dCBTi) and could be accessed remotely during lockdown. 
Method: We wanted to know if dCBTi could work for people experiencing a first episode of 
psychosis (FEP) and insomnia, during Covid19. We investigated how people use a dCBTi 
application. We studied whether symptoms of insomnia, psychosis, mood and worry changed 
when using dCBTi and how they related to each other. We also wanted to know what people 
with FEP and keyworkers in FEP services thought about the application. We used this 
information to build a model to describe how dCBTi can be used in services. 
Keyworkers working with people experiencing a FEP provided information about the study. If 
they wanted to take part, we contacted them to seek consent and check if they had insomnia. 
We met participants by videocall to measure psychosis, insomnia, mood, and Covid-19-
related worry before we began and after intervention. The intervention had 6 sessions, 
completed on an application. We recorded how people use the application. People with FEP 
and keyworkers had the option of taking part in interviews before and after they used it, to 
tell us about their expectations for and experiences of the application. This paper presents 
initial information from the study.  
Results: 10 people talked to us about participating. 3 did not want to participate and 1 did not 
do the assessments. 5 people participated.  Interviews with keyworkers helped us learn about 
their expectations for the application. They talked about people having lots of sleep 
difficulties, interventions they already have, beliefs about the application, and things about 
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service users and the service that might help or hinder the application being used. We used 
these results to build a model for how Sleepio might work or might not work in the service. 
Ethical Issues: Joining or not joining the study will not have effect anyone’s usual treatment. 
We will tell people that we will tell someone if we are worried about their safety or someone 
else’s. We will warn them that it might be distressing to use the application or to talk about 
their symptoms. We have permission from NHS ethics to start the study. All data will be kept 
secure and only researchers will see it. Participants’ data will not be linked to their name.  
Practical Applications: We want to share our results in different ways with other researchers, 
clinicians, and people with psychosis. This research could help services use dCBTi to help 




2.2. Abstract  
 
Background: Covid19 has impacted on population sleep and mental health; 
disproportionately affecting individuals with pre-existing mental health difficulties, including 
first episode psychosis (FEP). Given that insomnia is prevalent in FEP, associated with more 
severe psychosis, and can be ameliorated using digital Cognitive Behavioural Therapy (dCBTi); 
it may provide a viable treatment target during Covid19.  
Aims: We present preliminary data from a mixed-methods process evaluation of the 
implementation of dCBTi (Sleepio) in FEP services in NHS Scotland, informed by the MRC 
complex interventions framework. We aimed to collect data on the implementation of 
Sleepio, characterise service user symptomatology, and elicit service user and clinician 
expectations for Sleepio. We provide a working logic model of implementation. 
Method: People experiencing FEP and insomnia were eligible to access Sleepio. 
Implementation data was recorded and summarised (service integration, referrals, eligibility, 
consenting). Consenting service users’ sleep, psychosis, mood and Covid19-worry were 
assessed and summarised. Service users and keyworkers were invited to participate in semi-
structured interviews regarding expectations for Sleepio implementation. Interviews were 
recorded and transcribed. Framework analysis was used to analyse interviews.   
Results: 10 service users were referred. 3 declined to participate and 1 did not engage. 5 were 
eligible to participate and completed assessment.  Interviews revealed facilitators and 
barriers to Sleepio implementation related to: sleep difficulties, existing interventions, beliefs 
about Sleepio, service user factors and service-based factors.  
We provide initial description of the implementation of Sleepio dCBTi application in FEP 






Coronavirus-19 (Covid19), quarantine, restrictions to lifestyle and impacts on health and 
social care provision have challenged population mental health (Dean et al., 2021). The 
impacts of Covid19 and other pandemics increase insomnia and sleep disorder, low mood, 
anxiety and overall psychological distress (Brooks et al., 2020, Casagrande et al., 2020, 
Hossain et al., 2020, Lin et al., 2021, Yan and Huang, 2020). Morin and Carrier (2021) found a 
high rate of acute insomnia in the general population during Covid19, with a risk of this rate 
increasing (Casagrande et al., 2020). Covid19-related worry, depression symptoms and 
anxiety are each associated with increased insomnia (Kokou-Kpolou et al., 2020, Voitsidis et 
al., 2020, Wright et al., 2020). In Scotland, Covid19 reduced psychological wellbeing and 
increased sleep problems, particularly in those with pre-existing mental health difficulties 
(Public Health Scotland, 2020). There is therefore a need for scalable insomnia interventions, 
which can be delivered within the current context. 
People with pre-existing mental health conditions are disproportionately affected by mental 
health impacts of pandemics (Brooks et al., 2020) and experience poorer psychological 
outcomes during Covid19 (Kokou-Kpolou et al., 2020, Li et al., 2020, O'Connor et al., 2021). 
People recovering from a first episode of psychosis (FEP) are one such group. Psychosis 
describes a group of symptoms including disorganised thoughts and speech, voice-hearing, 
visual hallucinations, unusual strongly held beliefs (together referred to as ‘positive 
symptoms’); alogia, avolition, asociality, anhedonia and reduced affect expression (together 
referred to as ‘negative symptoms’; Wigman et al., 2011). This population present with 
mental, physical and social comorbidities (Gates et al., 2015), which may further increase their 
vulnerability to distress (Wright et al., 2020). Covid19 may increase the risk of developing 
psychosis (Brown et al., 2020, Valdés-Florido et al., 2021) and may increase psychosis 
symptomatology (Kozloff et al., 2020, Strauss et al., 2021). 
Outwith Covid19, sleep disorders are common in people with psychosis (Laskemoen et al., 
2019, Reeve et al., 2015). Common sleep disorder presentations include nightmares (~50%, 
Sheaves, Onwumere, Keen, Stahl, & Kuipers, 2015), sleep apnea (Sharafkhaneh et al., 2005) 
and hypersomnia (~30% Laskemoen et al., 2019; Hawley et al., 2010). However, insomnia is 
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considered the most prevalent, with estimates ranging from 7.9% to 75% (Batalla-Martín et 
al., 2020, Freeman et al., 2009, Mondal et al., 2018, Palmese et al., 2011). Sleep disorders are 
prevalent in FEP – around 80% present with a sleep disorder and comorbidity is typical (Davies 
et al., 2017, Ma et al., 2018, Reeve et al., 2019b).  The estimated prevalence of insomnia in 
those experiencing a first episode of psychosis is ~50% (Reeve et al., 2019b). 
Sleep disorder and insomnia have been explored as contributing and causal factors in 
experiencing psychosis (Dolsen et al., 2014, Harvey et al., 2011, Koyanagi and Stickley, 2015). 
Sleep disorder predicts psychotic-like experience in the general population (Freeman et al., 
2011, Freeman et al., 2012, Sheaves et al., 2016), symptoms in prodromal populations 
(Lunsford-Avery et al., 2017, Lunsford-Avery et al., 2015, Poe et al., 2017) and in early 
psychosis (Lunsford-Avery et al., 2015, Reeve et al., 2019a, Tan et al., 2001). In people with 
early or established psychosis, severity of sleep disorder is related to increased positive 
psychosis symptoms, increased cognitive disorganisation, and reduced affect (Chung et al., 
2018, Davies et al., 2017, Kilicaslan et al., 2017, Reeve et al., 2018, Reeve et al., 2019b). The 
relationship between psychosis and insomnia occurrence is bidirectional (Reeve et al., 2018, 
Reeve et al., 2015).  
In the general population, the relationship between paranoia and sleep is mediated by mood 
disorder (Freeman et al., 2011, Freeman et al., 2009, Taylor et al., 2015). In psychosis, sleep 
disorder and psychosis symptomatology remain related to mood (Dolsen et al., 2014, Reeve 
et al., 2018). Models of paranoia and persecutory delusions suggest that anxiety, depression 
and worry link the development of sleep disorder and paranoia (Freeman et al., 2009, Reeve 
et al., 2015). In the current context of Covid19-related worry and Covid19 regulations, sleep 
may deteriorate in people affected by FEP, impacting on mood and psychosis 
symptomatology. 
The relationship between sleep disorder and psychosis symptomatology has led to 
exploration of sleep as an intervention target (Freeman et al., 2015, Waite et al., 2020). 
People with psychosis appreciate sleep disorder intervention (Waters et al., 2015). Insomnia 
is a tractable clinical target in this population and Cognitive Behavioural Therapy (CBTi) shows 
promising results in reducing insomnia and potentially paranoia (Chiu et al., 2018, Freeman 
et al., 2015, Myers et al., 2011). Whilst CBTi may be effective, it cannot be scaled to meet the 
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need in this population (Espie, 2009, Reeve et al., 2019b). In the current context, there is an 
opportunity for digital psychological interventions, delivered remotely. Digital CBTi (dCBTi) is 
effective in improving insomnia (Seyffert et al., 2016). dCBTi application Sleepio (Big Health 
Ltd) has a comparative efficacy to in-person CBTi (Espie et al., 2012). Freeman et al. (2017) 
found Sleepio reduced insomnia, hallucinations and paranoia in a non-clinical population. 
Additionally, digital interventions are increasingly used in FEP populations (Rus-Calafell and 
Schneider, 2020) and service users are positive about their use (Bucci et al., 2018). 
Sleepio provides a psychotherapeutic intervention which can be offered remotely in the 
context of Covid19. This intervention targets insomnia, a common comorbid difficulty in FEP 
and common impact of the pandemic. Whilst highly scalable, dCBTi is a complex intervention 
for a multifaceted problem. The intervention comprises multiple interacting components 
which are implemented in a complex National Health system composed of a complicated 
population, staff factors, service user factors, and service factors (Craig et al., 2008). We 
therefore intend to conduct a process evaluation of the implementation of the Sleepio 
intervention through the lens of the Medical Research Council Complex Interventions Process 






2.4.1. Aims and Objectives 
We aimed to collect preliminary data to build a working logic model of digital CBTi 
implementation in NHS Scotland FEP services. The data comprises: a description of the initial 
process of implementation, characterisation of participating service users’ symptomatology, 
and framework analysis of service user and keyworker expectations for Sleepio intervention. 
 
2.4.2. Design 
Informed by the Medical Research Council (MRC) process evaluation for complex 
interventions framework (Moore et al., 2015; Figure 5); the overarching project is a 
prospective, non-randomised process evaluation of Sleepio implementation in a FEP service 
in NHS Scotland, in the context of Covid19. Process evaluations aim to explore components 
of complex interventions, their implementation, and how stakeholders interact with them 
(Maar et al., 2017, Moore et al., 2015). They allow theories of implementation to be 
developed and elucidate factors that will likely impact upon future efficacy evaluations (Maar 
et al., 2017). A logic model is being developed to graphically describe the process of Sleepio 
implementation as adjunct to usual care of people recovering from FEP.  
 
Figure 5. Process evaluation of complex interventions framework demonstrating key functions and 
components (blue boxes) of process evaluation and relations among them (Moore et al; 2015).  
Reproduced with permission. 
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This Major Research Project (MRP) provided initial data for a larger implementation study (for 
MRP proposal, see Appendix 2.2, for protocol see https://osf.io/2ja3s/). The wider project will 
continue to collect implementation data to understand the mechanisms of Sleepio’s impact, 
outcomes and other factors acting upon the model. 
 
2.4.3. Approvals and Ethics 
The study has approval from the West of Scotland Research Ethics Service (ID 21-WS-0010; 
Appendix 2.3.), NHS Greater Glasgow and Clyde (ID GN21MH015; Appendix 2.4.), and service 
management (Appendix 2.5.). A controller-to-controller agreement was created between 
NHS Greater Glasgow and Clyde and the University of Glasgow. A contract was instigated 
between Big Health and the University of Glasgow. The timeline of these required approvals 
and contracts was eight months (September 2020-April 2021). The implementation trial was 
registered on ClinicalTrials.gov (NCT05050201). 
 
2.4.4. Participants 
Participants were service users of an FEP service in NHS Scotland and keyworker clinicians. 
Eligible service users were 16-35yrs old and had access to a device to use the application. They 
were required to pass screening for insomnia. Service users were ineligible to participate if 
their psychosis was thought to be organic, they were acutely unwell (contact with crisis team 
or hospitalization within the last month), had a moderate or severe learning disability, 
insufficient English to understand the application, or could not give informed consent. Eligible 
staff participants held the role of keyworker and were currently employed by the service. 
Keyworkers were community psychiatric nurses or occupational therapists. 
2.4.5. Procedures 
To establish study referrals and implementation, the study protocol was presented at the 
service journal club and each area multidisciplinary team meeting by researcher FR. Weekly 
emails were sent to service clinicians to maintain awareness about the study. Researcher FR 
met informally with 12 keyworkers to discuss service users who may be suitable for referral 
and to clarify eligibility criteria. Ongoing recruitment was prompted via weekly email to all 
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clinicians and discussion at psychosocial intervention supervision by author MS. Recruitment 
to the study took place over 11 weeks, between 20/04/2021 and 09/07/2021. 
2.4.5.1. Keyworker Participants 
Keyworkers were given an information leaflet describing the study, detailing i) eligibility 
criteria, ii) the pathway for recruiting service users and iii) the role of keyworkers as 
participants.  
Keyworkers were given the opportunity to participate in semi-structured interviews with FR 
via Microsoft Teams videocall; about their expectations of Sleepio, and anticipated barriers 
and facilitators to its implementation. Interested keyworkers were provided with a Participant 
Information Sheet and Consent Form by email. Information Leaflets, Participant Information 
Sheets and Consent Forms are available at https://osf.io/2ja3s/. Participating keyworkers 
completed consenting procedures on Microsoft Teams and returned signed Consent Forms 
by email. Interviews were conducted by researcher FR, who is a clinician in the FEP service. 
Participants took part in interviews from private spaces; including their work, home, and car. 
Interviews lasted 24 to 35 minutes. Reflective notes were recorded after each interview. All 
interviews took place prior to service users beginning the intervention. Interviews were 
audiovisually recorded and transcribed and recordings were checked against transcriptions to 
ensure these were verbatim. Identifiable information was manually removed (e.g. service 
users’ names). Recruitment was continued until no further keyworkers expressed interest in 
participation.  
2.4.5.2. Service User Participants 
Keyworkers in the service were offered the opportunity to meet informally with FR to learn 
about the study and consider service users who may be eligible.   
Service users experiencing sleep difficulties were provided with an information leaflet by their 
keyworker. Interested persons were sent a Participant Information Sheet and Consent Form 
by post. Information Leaflets, Participant Information Sheets, and Consent Forms are 
available on https://osf.io/2ja3s/. Researcher FR called potential participants to give them the 
opportunity to ask any questions. They were encouraged to speak to others about potential 
participation. Participants completed consenting processes on an Attend Anywhere videocall 
and returned signed Consent Forms by post.  
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Participants were given the option to participate in semi-structured interviews prior to 
assessment, exploring their expectations of Sleepio, and anticipated barriers and facilitators 
to its implementation.  Following consenting procedures, eligibility screening was 
undertaken, including the Sleep Condition Indicator-2 item insomnia screening tool (SCI-02; 
Espie et al., 2014, Luik et al., 2019). This is a reliable and validated screening measure, which 
correlates with insomnia measures. Where individuals’ score indicated that they may be 
affected by insomnia, they were eligible to participate.  
FR met with participants to complete initial assessment using Attend Anywhere. This 
comprised clinical assessment of participant sleep and completion of baseline 
symptomatology measures on Online Surveys (https://www.onlinesurveys.ac.uk/). Sleepio 
was launched and participants completed its initial assessment. The intervention period then 
began and adherence to and attrition from the intervention was collated. 
 
2.4.6. Sleepio Intervention 
Sleepio (Big Health Ltd) is a digital CBT intervention application, used on a computer or iOS 
smartphone. Sleepio is composed of six 20-minute sessions presented by an animated 
therapist, unlocked weekly. Participants complete initial assessment in the application and 
chose a treatment goal. Sleepio’s sessions are based on a 6-session CBTi protocol (Harvey, 
2002) and include: i) psychoeducation on sleep hygiene and processes; ii) cognitive 
components including restructuring, mindfulness, positive imagery, paradoxical intention 
training, and resolving thoughts about the day; and iii) behavioural components including 
sleep restriction, stimulus control, and relaxation techniques.  Participants book digital 
‘appointments’ with the therapist and receive prompts to complete them, enter sleep data, 
and complete the Sleep Condition Indicator on a weekly basis. The Sleepio algorithm tailors 
ongoing intervention based on input data about participants’ sleep, physical and mental 
health. Sleepio also provides access to online psychoeducation and a clinician-moderated 
user forum.  
Keyworkers were provided with access to the ‘Sleep Clinic’, Sleepio’s clinician interface. Here, 
allocated professionals can observe session completion rates, data entered and Sleep 
Condition Indicator scores for participating service users. Service users explicitly consented to 




2.4.7. Data Collection  
2.4.7.1. Process of Implementation 
Implementation data aimed to capture the ‘pathways’ of the study and service users in the 
study. We summarised i) the pathway of approval for Sleepio in the context of a FEP service 
(required approvals, contracts, timelines), ii) the establishment of the referral pathway 
within the service (awareness raising events, meeting with clinicians) and iii) recruitment 
into the study (rates of referral, rates of consenting, reasons for not consenting, eligibility, 
reasons for ineligibility, completion of initial assessment).    
 
2.4.7.2. Characterisation of Symptomatology 
We aimed to characterise service users’ insomnia, psychosis symptoms, mood, and Covid19-
related worry prior to starting Sleepio intervention.  
Insomnia symptoms were assessed using the Insomnia Severity Index (ISI; Bastien et al., 
2001). This brief self-report questionnaire assesses the severity of night-time and day-time 
components of insomnia. It is widely used, reliable and valid, and is responsive to change.  
Participants will be regularly prompted within Sleepio to complete the full Sleep Condition 
Indicator (SCI; Espie et al., 2014). The SCI is an 8-item scale measuring sleep problems against 
DSM-5 criteria for Insomnia Disorder. It has good validity and reliability and is sensitive to 
change. These scores will be available for analysis for the overarching project.   
Psychotic symptoms were assessed using the Specific Psychotic Experiences Questionnaire; 
hallucinations subscale (SPEQ-H; Ronald et al., 2014) and Revised Green et al Paranoid 
Thought Scales (R-GTPS; Freeman et al., 2021) The SPEQ is a transdiagnostic self-report 
measure of psychosis symptomatology, with subscales for paranoia, hallucinations, cognitive 
disorganization, grandiosity, anhedonia, and parent-rated negative symptoms. The R-GPTS is 
a two-factor measure of paranoid thoughts, with subscales distinguishing persecutory 
ideation and ideas of social reference.  
Mood symptoms were assessed using the Depression, Anxiety and Stress Scales 21 item 
(DASS-21; Antony et al., 1998). The DASS-21 is a widely used measure of depression, anxiety, 
and stress.   
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Covid19-related worry was assessed using the Fear of Covid19 Scale (Ahorsu et al., 2020). This 
scale is new but has relatively good psychometric properties and is validated (Bitan et al., 
2020, Perz et al., 2020, Soraci et al., 2020). 
2.4.7.3. Qualitative Interview Data 
Semi-structured interviews were employed to ascertain service user and staff expectations of 
Sleepio implementation. Interview schedules were developed to explore service users and 
keyworkers expectations for digital intervention for sleep difficulties in EIP services; including 
their perceptions of any barriers and facilitators and anticipated mechanisms of change.  
Interview schedules are available on https://osf.io/2ja3s/. The schedules were developed 
from the MRC Complex Interventions Process evaluation framework (Moore et al., 2015), 
including questions exploring the i) context of the intervention, ii) factors of its 
implementation and iii) the anticipated mechanisms of its impact. The research team 
developed questions collaboratively in discussion. We aimed to develop dialogue based on 
the key topics of the guide, whilst allowing exploration of emerging themes. 
 
2.4.8. Data Management  
Raw data were stored within NHS Greater Glasgow and Clyde on a password-protected 
server. Anonymised data were stored in a password-protected server in the University of 
Glasgow. Anonymised Sleepio usage data were collated by Big Health Ltd and transferred to 
the University of Glasgow. 
 
2.4.9. Analysis 
2.4.9.1. Process of Implementation 
Summary descriptive and quantitative information is provided for implementation 
measurements.  These comprise: approvals and time taken to procure necessary approvals 
(data protection, ethical, contracts), number of presentations to the FEP service, number of 
information sessions delivered, number of meetings with service keyworkers, rate of referral, 
rate of consent to participate, reasons for not consenting, rate of eligibility, and the 
proportion completing Sleepio initial assessment. 
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2.4.9.2. Characterisation of Symptomatology  
Symptomatology measurements are quantitatively described using measures of central 
tendency and dispersion. Our study was not designed nor powered to detect statistical 
differences in measures over time.  
2.4.9.3. Qualitative Framework Analysis  
We aimed to explore service user and keyworker expectations as an individual and collective 
phenomenon, within the context and social reality of participants (Holloway, 2005). Whilst 
framework analysis is not bound by an epistemological position (Ritchie and Spencer, 2002), 
we took a post-positivist contextual constructionism stance. The results of the analysis were 
considered subjective from the position of both participants and the researcher, and specific 
to their context and to individuals (Madill et al., 2000). We report our qualitative analysis as 
per the COREQ checklist (Appendix 2.6.). 
We used an inductive thematic framework analysis (Braun and Clarke, 2006, Ritchie et al., 
2003) to examine patterns of categories across our participants. As stated, the interview 
schedule framework was based upon the MRC Complex Interventions process evaluation 
framework (Moore et al., 2015). Ritchie and Spencer (2002) suggest that framework analysis 
is a useful approach for questions of context (e.g. ‘what is the context of Sleepio 
implementation?’) and strategy (e.g. ‘how can Sleepio be implemented in this FEP service?’). 
This approach allowed us to meet our aim of capturing expectations for Sleepio dCBTi 
intervention and its implementation, whilst allowing additional themes to inductively expand 
the framework (Ward et al., 2013).   
Video recordings of interviews and transcriptions were iteratively reviewed alongside 
reflective notes to familiarise researcher FR to the data. Initial indexing to the thematic 
framework and inductive coding of emergent themes was undertaken by FR (see Appendix 
2.7.). Themes were reviewed and refined through interaction with the raw data and 
discussion with co-investigators at research meetings. Categories and subcategories were 
charted and mapped into a framework matrix. The final phase of analysis was to select 
representative quotes to illustrate the subcategories and synthesise the results. 
Researcher FR (PhD) is a female trainee clinical psychologist, trained in qualitative 
methodology specifically Interpretative Phenomenological Analysis. At the time the 
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interviews were undertaken, she worked in the FEP service and had existing professional 
relationships with some keyworker participants. The field researcher for the project works for 
the service as a principal clinical psychologist and the chief investigator collaborates 
frequently with the service to undertake research. This provided the research team with 
additional insight into barriers and facilitators to Sleepio implementation, but also acts as a 
source of bias in interpretation, influencing the results. Reflective notes kept during the data 
collection process helped the researcher FR reflect on sources of bias. 
As the service has a small staff group, we report limited summary demographic information 
about keyworker participants (gender and professional group only) to reduce the risk of 
deanonymization.  However, researcher FR was familiar with keyworkers, their professional 
role in the team, and relative experience when undertaking and analysing interviews.  
 
2.4.10. Preliminary Logic Model   
A logic model of Sleepio implementation in FEP services is being developed. A preliminary 
version is presented and discussed, aiming to shape the ongoing implementation of Sleepio 







2.5.1. Process of Implementation 
The service population includes ~250 service users, with ~150 new service users per year. 
Around 80% would be expected to experience clinically significant sleep difficulties and 
around 50% to experience Insomnia Disorder (Reeve et al., 2018). Ten service users expressed 
interest in the study and were sent participant information. These referrals originated from 
three of four FEP area teams (five from the north east team, two from the north west team, 
and three from the south team) and seven individual keyworkers. Three declined to 
participate for the following reasons: involved in too many interventions, did not want their 
GP to be notified, and sleep improved. One potential participant did not engage with 
assessment processes. Five participants completed screening and met criteria for 
participation (SCI-02 mean score 1.4, range 0-2; Table 6.). Four participants intended to use 
Sleepio on a computer or laptop and one intended to use an iPhone. Five participants 
completed study initial assessment (sleep assessment and completion of measures) and were 
set up with the intervention (age range 21-33, mean 28.4yrs, 3/5 male, all White British). 
At present, four service users have started using Sleepio (one paused their use of the 
intervention after starting, due to losing access to a suitable device). Two have not begun the 
intervention. 
2.5.2. Characterising Service User Participants 
Clinical assessment of sleep indicated that all consenting service users were experiencing 
insomnia (Table 5). Additionally, some participants described narcolepsy symptoms, 
nightmares or sleep paralysis. 
Table 5. Sleep difficulties reported in clinical sleep assessment.  
Sleep Difficulty Component n Participants 
Insomnia  5 
 DIS 5 
 DMS 5 
 EMA 4 
Nightmares  2 
Narcolepsy  1 
Sleep Paralysis  1 
DIS = difficulty initiating sleep, DMS = difficulty maintaining sleep, EMA = early morning awakening  
64 
 
All consenting service users (n=5) completed assessment measures (Table 6). Participant 
scores on the ISI indicated that all were experiencing moderate or severe clinical insomnia. 
SPEQ-H scores indicated that participants were experiencing low levels of hallucinations. On 
the R-GPTS, three participants scored in the average range and two in clinical ranges for ideas 
of reference. Three participants scored in the average range and two in clinical ranges on 
persecutory beliefs. On the DASS-21, two participants scored in normal to mild ranges and 
whilst three others reported some moderate to extremely severe mood difficulties. Fear of 





Table 6. Participant scores and allocated descriptive categories on assessment measures. 
 
IQR = interquartile range.
Measure n Participants Subscale Median score Range IQR
Sleep Condition Indicator 5 2 0 to 2 1
No Insomnia (n) Probable Insomnia (n)
0 5
Median score Range IQR
Insomnia Severity Index 5 19 18 to 26 3
No Insomnia (n) Subthreshold (n) Clinical Insomnia - Moderate (n) Clinical Insomnia - Severe (n)
0 0 3 2
Median score Range IQR
Revised Green et al. Paranoid Thoughts Scale 5 Reference 8 1 to 25 6
5 Persecution 4 0 to 31 21
Average (n) Elevated (n) Moderately Severe (n) Severe (n) Very Severe (n)
3 1 0 1 0
3 0 0 1 1
Median score Range IQR
Specific Psychotic Experiences Questionnaire 5 Hallucinations 8 1 to 16 3
Median score Range IQR
Depression, Anxiety and Stress Scales - 21 5 Depression 16 0 to 28 12
Anxiety 8 4 to 20 12
Stress 18 8 to 30 6
Normal (n) Mild (n) Moderate (n) Severe (n) Extremely Severe (n)
Depression 1 0 2 1 1
Anxiety 2 1 0 1 1
Stress 1 2 1 1 0
 
 
2.5.3. Expectations of Sleepio Intervention 
The qualitative sample was 8 keyworkers (KW, 4 female, 4 male), covering each area team. 
No keyworker dropped out. Keyworkers were community psychiatric nurses or occupational 
therapists. No service user chose to complete a pre-intervention interview. 
Table 7. summarizes the 6 categories and sub-categories developed from thematic framework 
analysis and specifies how many participants contributed to each sub-category. These 
categories and subcategories contributed to the preliminary logic model (see 2.5.4.).  
Table 7. Categories and subcategories from framework analysis. 
 
Categories are elucidated below. Quotation clarifications are represented by square brackets 
[ ]. Where material is omitted, we indicate this with ellipses [...]. Page and line number are 
provided for quotes. 
 
Category 1. Sleep Difficulties  
Category 1.1. Awareness of the Need  
Keyworkers spoke about the high prevalence of sleep disorder in the FEP population, “I think 
within our specialty service for psychosis sleep is... You know, a huge issue” (KW3, pg.1, L.12). 
Category Subcategory KW1 KW2 KW3 KW4 KW5 KW6 KW7 KW8
Sleep Difficulties Awareness of the Need Y Y Y Y Y Y Y Y
Symptomatology and Sleep Y Y Y Y Y Y Y Y
Diverse Sleep Difficulties Y Y Y Y Y Y Y Y
Contributing Factors Y Y Y Y Y Y Y Y
Impact of Covid19 Y Y Y Y N N Y N
Existing Interventions Keyworker Interventions Y Y Y Y Y Y Y Y
Medication Y Y Y N Y N N Y
Beliefs about Sleepio Helpful Y Y Y Y Y Y Y Y
Safe Y Y Y Y N N Y Y
Concerns Y Y Y Y Y Y Y Y
Tool in Toolbox N Y N Y Y Y Y Y
Anticipated Mechanism Y Y Y Y Y Y Y Y
Interaction with the Service Y Y Y Y Y Y Y Y
Service User Facilitators and Barriers Comfort with Technology N N Y Y Y Y Y Y
Digital Access Y Y Y N Y Y Y Y
Stage and Stability Y Y Y Y Y Y Y Y
Priorities for Care Y Y Y Y Y Y Y N
Service Facilitators and Barriers Talking or not Talking about Sleep Y Y N Y Y Y Y Y
Sleepio and Resource Restrictions N Y Y Y Y Y Y Y
The Role of a Keyworker N Y N Y N Y N Y
Active Engagement and Connection N Y Y Y Y N Y Y
Embracing Research and Innovation N Y Y Y N Y Y Y
Familiarity Needs Y Y N N N Y N N
67 
 
They felt that addressing sleep was important for recovery, “as a service, we all understand 
the impact that sleep can have in terms of someone's recovery, in maintaining their health 
and wellbeing” (KW3, pg.5, L.214-215).   
 
Category 1.2. Symptomatology and Sleep 
Keyworkers recognised a relationship between sleep and psychosis, “in turn [after sleep 
dysfunction] seeing people presenting with, I suppose, sort of like early signs of, you know, a 
psychotic presentation. That [relationship] is probably the, the most common […] when people 
are first presenting” (KW5, pg.1, L.12-14). Some keyworkers felt that sleep was more related 
to negative symptoms, “it's not as if people are kinda more, more psychotic if you like, more 
positive symptoms, I’ve not really seen that that much, but I think more like it... If you think of 
the syndrome, the negative kinda syndrome […] is that kinda linked?” (KW7, pg.3, L.116-118). 
Mood was also characterised as related to sleep, “it might be, the, you know the person is not 
depressed, but we don't want to get to the point where these sleep problems are, are 
becoming to the point where they're having a negative impact on their mental health” (KW2, 
pg.2, L.85-87). One keyworker felt that Covid19 impacted the relationship between sleep and 
psychosis symptomatology “I don’t know, is it [sleep problems], because kinda covid and the 
stress, the kinda flipping your sleep pattern, the impact that has on your, you know, kinda 
biological physical health and stuff? Or is that part of the negative kind of syndrome of 
psychosis or… Is it partly kinda mood or affecting mood, you know, or is it a combination of all 
that together?” (KW7, pg.3, L.118-122).  
 
Category 1.3. Diverse Sleep Difficulties 
Insomnia was not always the primary sleep difficulty reported. Keyworkers spoke about 
service users experiencing hypersomnia, nightmares, sleep paralysis, and circadian rhythm 
dysfunction. They felt that a variety of sleep disorders other than insomnia may impact on 
the implementation of the intervention, “[where there are] no specific issues with falling 
asleep or staying asleep, just more maybe that their routines maybe not the most 
established... Maybe the Sleepio study wouldn't be particularly helpful for that” (KW3, pg.7, 
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L.280-282). Other keyworkers felt that Sleepio would be useful for a diverse range of 
difficulties, “to be honest near enough everybody would benefit from that type of intervention. 
'Cause I think even using a CBT type model for sleep, I think it's just such a good tool for life 
[…] there are lots of people who are maybe not having severe issues but still getting times 
where sleep is disturbed, so I don't necessarily think it would just be something that I would 
be thinking about the, the worst-case insomnia. You know, I think everybody can benefit from 
the intervention” (KW6, pg.8, L.325-330) 
 
Category 1.4. Contributing Factors 
Keyworkers had an awareness of behavioural, environmental, biological and psychological 
factors contributing to poor sleep, “a lot of the caseload is I feel, lack of structure and routine 
is causing people, they’re like, always staying up late at night and then kinda sleeping till 
afternoon during the daytime” (KW4, pg.1, L.19-21). These factors were linked to 4.3. Stage 
and Stability of the service user, “often sort of what you find, if people, in early stages of 
recovery, aren't doing particularly much, em, there, there’s a good chance they’re not going 
to be overly tired when they go to bed” (KW5, pg.2, L.56-58).  
Category 1.5. Impact of Covid19 
Keyworkers felt that Covid19 had impacted on service user sleep, “Absolutely yeah [Covid19 
has had an impact]. I’d say yeah for a number of reasons. I'd say partly because the, the, 
maybe the usual structure and routine is not there. So, groups and activities or work, em, that's 
been taken away, so that lack of structure and routine. And again, I think, I've noticed a lot of 
people talking about sort of a more vivid dreams and things since lockdown. So yeah, that, 
that's been quite a common theme. Actually, having this is, lots of people talking about quite 
vivid dreams” (KW4, pg.2, L.66-70).  
 
Category 2. Existing Interventions 
Category 2.1. Keyworker Interventions  
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Keyworkers reported using sleep hygiene and diaries, “Finding out a wee bit more about their 
sleep patterns first, so, sleep diaries, sleep hygiene and get some leaflets that I would refer to 
as well. There's a booklet on sleep that often give to some patients. Em, we, it tends to be 
basic, trying to do basic interventions” (KW8, pg.2, L.61-64). They felt existing interventions 
were limited, “I don't think we have a lot of interventions though. I mean, I think we've got. 
Some… I think we’ve all got a couple of things up our sleeve that will use. That are, you know, 
very simple things. And then you've got medication. But other than that, there's not a great 
deal to be honest” (KW2, pg.3, L.119-121), and variable in their delivery and keyworker 
confidence, “every keyworker is probably a bit different in what they offer and what they're 
comfortable and confident in offering. So, I think that's something that's really important, to 
consider, because it's not without intention of helping somebody, but I don't think there’s 
necessarily a consistent approach because everybody's got different levels of experience and 
maybe... compete-confidence in delivering certain interventions” (KW6, pg.2, L.55-60). 
 
Category 2.2. Medication 
Keyworkers identified beliefs that medication was efficacious in the short term but was not 
effective longer term. This belief strengthened their appetite for Sleepio intervention, “CBT is 
so effective, is more effective than medications [in changing sleep]. Better than medication, 
because medication is just a short-term intervention. It's, you know, they can't, it's not the 
long-term solution” (KW1, pg.3, L.97-77). Keyworkers seemed to prefer a non-drug 
intervention, “if we can [improve sleep] without, em, giving them chemical interventions, 
then, that's a good sign” (KW2, pg.7, L.270-271) and felt that service users would appreciate 
a non-drug intervention, “I think a lot of our young people would really, ah, you know, value 
that and appreciate that [alternative to medication]” (KW3, pg.4, L.136).  
2. Existing Interventions was linked closely to 5.2. Resource Restriction, as there was a view 
that sleep intervention resources were limited. 
 
Category 3. Beliefs about Sleepio 
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Category 3.1. Helpful  
Keyworkers held positive views about the helpfulness and efficacy of digital intervention, “I 
have not read up on anything or research, but I really do think [digital interventions] work. I’ve 
got belief in them. From time to time I use them myself. You know, family members use them. 
They do work.  I hear people saying positive things about them, so I just say that to patients 
as well. These things, do help. Try and encourage people to kinda pull them out and use them” 
(KW7, pg.5, L.201-204). They felt Sleepio specifically would be helpful, “I think it be fantastic 
[to have access]… Obviously CBT is so effective” (KW1, pg.3, L.96-97).   
 
Category 3.2. Safe 
Keyworkers identified believing that Sleepio intervention was safe, “I don't think it's going to 
do any harm for anybody” (KW2, pg.7, L.266). They also spoke about Sleepio as ‘Covid19-safe’, 
“I think especially during Covid's times, people might feel safer accessing something digitally 
rather than having that kind of face-to-face contact […] could offer some more safety and 
security if it was digital” (KW3, pg.3, L.94-99). 
 
Category 3.3. Concerns about Sleepio  
Keyworkers expressed some concerns about Sleepio implementation in FEP services. Despite 
belief in its safety, they were worried that it may increase distress and paranoia about 
technology and being monitored, “It would be maybe more traumatic for them if they're on 
their own trying to do this from home and maybe not fully understanding it, and the app’s 
talking to them, and thinking about somebody who's going through psychosis, that could 
possibly be problematic” (KW4, pg.6, L.211-213). Some keyworkers thought that face-to-face 
interventions may be superior, “I think face-to-face CBT would probably be more effective” 
(KW1, pg.3, L.106). Other concerns mentioned by only one keyworker were the ease of 
disengagement, increased worry about sleep, and the remote nature of monitoring feeling 




Category 3.4. Tool in the Toolbox 
Keyworkers conceptualised Sleepio as an additional tool in the toolbox for both keyworkers 
and service users, “I hope [Sleepio] would give them another tool, as I say, in their toolkit, 
something that they can go to as and when they need it” (KW8, pg.4, L.142-143). They 
indicated a relaxed approach to using the intervention, “I feel sort of like you're not gonna use 
every single intervention under the sun with a patient. But the more that you've got, I guess, 
sort of like ‘in your locker’, to be able to sort of, like, discuss or offer, the better. It is nothing 
but a good thing” (KW5, pg.6, L.210-212).  
 
Category 3.5. Anticipated Mechanisms 
Keyworkers explored anticipated features of Sleepio. These included education and 
knowledge about sleep and behaviour change, reducing distress around sleep disturbance, 
reduced fear of relapse, service user autonomy, and flexibility of access to the app. Autonomy 
was seen as differentiating Sleepio from other interventions offered by the service, “I suppose 
the good thing is […] it gives the patient ownership over their own care... It’s something that, 
I think, yeah, I think our patients could probably do with a bit more of. Em, I think they maybe 
lean a wee bit more heavily on keyworkers in particular, rather than maybe having taken on 
that responsibility for their own care” (KW8, pg.3-4, L.122-130).  
 
Category 3.6. Interaction with the Service 
Keyworkers believed there was a role for service professionals in promoting the application, 
supporting engagement, helping with any difficulties, checking on progress via the Sleep Clinic 
interface, and providing additional input where needed. This was linked to 5.4 Engagement 
and Connection, “I suppose the keyworker tends to be the person that has the most contact 
with the person? So just, so I know how that person is been getting on, not just in terms of the 
sleep? How they’ve been, been engaging with this? Are we noticing in it, any improvements 
are noted or are things getting worse and it gives us the opportunity to bring that to an 
appointment and see, you know, I notice you've not been sleeping as well this week. Is there 
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anything going on? Is there anything you're worried about? And I suppose it just breaks down 
every barrier in terms of starting those conversations with someone” (KW3, pg.8, L.332-338). 
Keyworkers spoke about the importance of all professionals providing a unified message in 
implementation, “I think having access to the support of the different professionals as well... 
would be helpful, because we all sing from the same hymn sheet in a way so they would be 
able to, em, ask questions of who ever seen them” (KW8, pg.6, L.229-230). 
 
Category 4. Service User Facilitators and Barriers 
Category 4.1. Comfort with Technology  
Keyworkers felt that FEP service users were generally comfortable with technology and digital 
interventions like Sleepio would be suitable, “I actually think this is quite exciting, this app, 
because it's the way things are going these days. And again, our, the age group of the people 
we support are proper, like, so tech savvy, and I think it will be a lot of people will be keener 
to do that than possibly… it's obviously it's not for everybody, but I do think a lot of people will 
be keener to, to, or more receptive to a sort of digital thing as opposed to face to face sort of 
intervention” (KW4, pg.3, L.109-116). 
 
Category 4.2. Digital Access 
Digital literacy and access were identified as crucial factors in accessing Sleepio, “I think the 
biggest issue with it is a-accessibility for everyone. There are some people who perhaps don't 
have a smartphone, smartphones for instance, and you won't be able to access it that way. I 
guess that's probably the biggest thing for me... The only kind of real barrier I guess, like, is 
everyone being able to access it” (KW5, pg.4, L.141-144). Keyworkers linked this theme to 4.3. 
Stage and Stability, noting that social factors were related to lack of digital access, “Some 
people don’t have access to technology. Most younger folk will have access to technology, I 
think, but, uh, I see a lot of people with really chaotic lifestyles. I don't, you know, they don't 
have, you know they may have a smartphone one week, but the next week it is in the pawn 




Category 4.3. Stage and Stability 
Keyworkers spoke about factors they thought would exclude service users from Sleepio. They 
thought that service users at an early stage of recovery or with continuing psychosis 
symptoms would not be appropriate, “I wonder if people who are still pretty, or still kinda 
experiencing symptoms and still pretty kinda, em, suspicious, or paranoid, or whatever, or 
distracted [may not be suitable]... Em, so I guess people in early recovery or in recovery ... 
they’re gonna participate more than people who are in early stages, starting to develop 
relationships with the team, are gonna be more kinda difficult for those reasons. You know, 
kinda, building up trust and, em… so I guess where they are at on their journey in terms of 
recovery, you know? Will impact on whether they take part” (KW7, pg.7, L.274-281). 
Keyworkers said they consider substance misuse an exclusion criterion for participation, 
“What I wonder about, maybe like drug use if somebody's heavily into substances, how? You 
know, how’s that's maybe, gonnae, it's gonna go. Because if, they will have been given a lot 
of that information and education and I guess I could see that the substances would maybe 
be a real barrier to actually engage in and make any benefits from it” (KW6, pg.6, L.234-236). 
Both factors were closely related to 4.4. Priorities for Care as keyworkers thought sleep may 
not be a priority and to 5.4. Engagement and Connection, as these factors may impact on 
engagement.  
 
Category 4.4. Priorities for Care 
Keyworkers believed that service users would have to be in a position to prioritise sleep in 
order to engage with the intervention, “I suppose you can only bring a horse to water. You 
can't make it drink.  Like you can only provide them with the advice and I suppose it is good to 
know. Em, If you know, I suppose when we're referring for psychology there is a level of their 
commitment required in order to get help [like for Sleepio]” (KW1, pg.6, L.209-212). They 
thought that keyworkers may believe sleep to be a priority when service users do not, 
“sometimes you know you, with certain interventions that can feel that way, like you know, I 
can see that this would benefit you, but you know, for them it's you know. It's not on the radar 
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at all […] because there may be other people who, even though you think they've sleep 
concerns it doesn't really seem on their radar. They don't bring it up. They don't seem that 
bothered about it. Uh-huh, yeah, it's not something that we're willing or wanting to address 
just now. It's not a priority” (KW5, pg.7-8, L.291-303).  
 
Category 5. Service Facilitators and Barriers 
Category 5.1. Talking or not Talking about Sleep  
Keyworkers reported that speaking about sleep is something they do routinely, and they did 
not anticipate any reluctance in bringing it up, “Any difficulties asking people [about sleep]? 
None. [Sleep is] something we talk about quite a lot and it's just like talking about the weather, 
really” (KW1, pg.5, L.197). However, in concert with 5.2. Resource Restrictions they thought 
that the resource constraints in the service can mean sleep is not discussed, “I think as a 
Keyworker sometimes […] it's the last thing on your mind. Em even when you go in with the 
intention of taking information and saying here we go […] it's just not on your radar when 
you're going in to see somebody” (KW6, pg.8, L.310-315).  
 
Category 5.2. Sleepio and Resource Restrictions 
Keyworkers felt the demands being placed upon the service and the resource constraint in 
keyworkers would act as a barrier to Sleepio implementation, “Again [barriers to the 
intervention] just comes down to workload again. […] I’ve never, knowing what the caseload 
sizes were like then, they’re much, much higher now. With probably less resources. So again, 
just comes down to workload and pressure on keyworkers” (KW7, pg.11, L.441-444). 
Keyworkers felt that Sleepio could lessen the demands on keyworkers by providing a sleep 
intervention which did not require heavy input from them, “So it kind of feels like. It's an 
intervention, but it's not necessarily all on the key worker to deliver that” (KW6, pg.5, L.176-
177). However, they were concerned that they would struggle to monitor service users’ use 
of the application due to resource, “I wonder how that would be because I could imagine 
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myself being outside somebody's house about to get into a visit and trying to log on and go 
right. What's going on? What’ve they actually done?” (KW6, pg.10, L.408-410).  
 
Category 5.3. The Role of a Keyworker  
Several keyworkers felt that the way service users viewed their role and the variety in their 
role was a barrier to implementing Sleepio, “as a keyworker you can kinda get separated. 
There's like ‘no, I want to talk to psychology about that’, or we’ll just do the housing just now. 
So that could... That's a kind of barrier, because you've got lots of hats on as a key worker” 
(KW4, pg.7, L.275-277). This related to the theme of 5.2. Resource Constraint, as a limited 
resource was split across many demands in the role.  
 
Category 5.4. Active Engagement and Connection 
Keyworkers believed that a strength of the FEP service was the active approach to 
engagement that professionals take to build a connection with service users. They thought 
that this would positively impact implementation of Sleepio and service user engagement 
with it, “because we use quite an assertive outreach approach with all our young people, I 
think that the keyworkers would have a really proactive part in supporting someone to engage 
in this study” (KW3, pg.5, L.209-211).  
 
Category 5.5. Embracing Research and Innovation 
Keyworkers felt the service embracing innovation and research would aid implementation of 
Sleepio, “Yeah, I think, I think with [service] it's been part and parcel of… My time at [service], 
there's always been different things and it's always to improve the service” (KW8, pg.8, L.328-
330), and service user engagement with Sleepio, “people do, like, we've got kinda, a lot of 
people previously in research. So, people have kinda, people do take part in it. You know they 
do want to, and they do want to help themselves and they do want to help others through 
research ... So, it’s how you kinda sell research to them. Not only would it help them, it would 
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also help other people. A lot of folk like that notion” (KW7, pg.8, L.327-331). Keyworkers felt 
that Sleepio was consistent with innovation in digital delivery during the Covid19 pandemic, 
“A lot of our contacts, I guess over the last year have moved to a bit of a digital platform, I'm, 
I guess that ties in with that, em … I guess it allows you to be more supportive for things like 
that” (KW5, pg.5, L.188-191).  
 
Category 5.5. Familiarity Needs 
Keyworkers felt that they would require increased familiarity and training in use of the 
application and Sleep Clinic interface in order to fully implement it, “is it possible for us to be 
able to get access to it as key workers to, you know, have a try or even. The position of using 
it ourselves? Yeah, I mean that's, that's maybe just maybe just me, but I would like to be able 
to talk to somebody as if I’ve experienced it as well, you know?” (KW6, pg.11, L.427-429). 
One identified that the anxiety they felt about the application (3.3 Concerns about Sleepio) 
was related to their lack of familiarity with it, “[I feel] Anxious {laughs} [about using the 
Sleep Clinic] … Just 'cause it's something that I’ve never done before. So, its fear of the 
unknown, really” (KW2, pg.9, L.347).  
   
 
2.5.4. Preliminary Contributions to Logic Model 
Whilst a full logic model cannot be elucidated, initial and hypothesised contributions can be 
mapped onto a working logic model for Sleepio implementation (Figure 6). The model’s 
features include contextual factors, the intervention inputs, known and theorised facilitators 
and barriers acting upon the implementation of the intervention, anticipated intervention 





Figure 6. Preliminary logic model describing the initial implementation of Sleepio.  
Black text represents elements arising from preliminary data. Green text represents hypothesised elements. Purple text represents elements not yet in place.  
 
 
2.6. Discussion  
2.6.1. Implementation of Sleepio 
This study presents preliminary data arising from a process evaluation of the implementation 
of dCBTi intervention in a FEP service in NHS Scotland. There were significant impacts to the 
study implementation timeline due to required approvals and contracts across the three 
contributing organisations. With efforts to advertise the study and integrate it into the 
service, the rate of referral was ten referrals in 11 weeks.  
Qualitative data suggests that service resource constraints may have impacted on sleep issues 
being explored and referrals made. Staff’s concerns about the complexity of sleep difficulties 
and their understanding of the relationship between sleep difficulties, psychosis, and mood 
symptoms may have also limited referrals. Clinicians identified applying additional referral 
criteria related to service user stability (e.g. considering substance misuse an exclusion 
criteria). Initial quantitative data suggest that referred service users were experiencing 
relatively mild symptoms of psychosis. Five of ten referred service users consented to 
participate to the study. These service users all self-identified as White British, which may not 
be representative of people experiencing psychosis (Cantor-Graae and Selten, 2005). The 
demographics and symptomatology characteristics of referred service users may present a 
basis for concern. Health inequalities based on protected characteristics including race and 
ethnicity may widen if digital health interventions are not equitably offered or adapted for all 
groups (Latulippe et al., 2017; Zhang and Walsham, 2021). Digital health innovations are 
known to increase the risk of health inequality for people experiencing severe mental ill-
health (Spanakis et al., 2021). In this, the use of digital methods compounds the health divide 
already experienced by people who lack access to devices, of minority ethnicity and/or who 
experience severe mental ill-health in an intersectional manner (Zhang and Walsham, 2021). 
It is therefore imperative that Sleepio implementation is considered with individuals of 
minority ethnicity and who are experiencing severe mental ill-health.  
All consenting participants were eligible for inclusion. Consenting service users reported 
moderate to severe insomnia, the presence of other sleep disorders, and a range of mood 
symptomatology from non-clinical levels to extremely severe depression and anxiety. 
However, psychosis symptomatology was reported to be low. Taken together with findings 
from framework analysis, this suggests that clinicians primarily referred service users who are 
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considered more stable in psychosis presentation, and for whom they consider sleep to be 
the outstanding difficulty or the driver of mood difficulties. Participating service users 
reported low levels of anxiety about Covid19. These measures were collected >1 year after 
initial Covid19 regulations and scores may have been different if the study was undertaken 
earlier in the pandemic.  
Currently no participants have reached the end of the 10-week intervention timeline. 
Preliminary application usage data suggests that service users have a mixed response to the 
application, with some using it on a weekly basis and others not starting the intervention. One 
participant stopped using Sleepio due to losing access to a device. People attending mental 
health services are disproportionately affected by digital poverty and exclusion (Tobitt and 
Percival, 2019; Spanakis et al., 2021). We did not provide a device nor data to participants, 
which is likely to induce inequalities in access and increase the impact of digital poverty, as 
represented in the working logic model. Furthermore, we are aware that there is a synergistic 
relationship between poverty, race and ethnicity and mental ill-health in promoting digital 
exclusion (Zhang and Walsham, 2021). It is critical that we monitor indicators of exclusion in 
ongoing data collection and consider the impacts this has on the applicability and limitations 
of the resulting logic model.  
 
2.6.2. Expectations for Sleepio 
We elucidated keyworkers’ perceived barriers and facilitators impacting on the process of 
Sleepio implementation.  Overall, keyworkers recognised the importance and variety of sleep 
difficulties in the FEP population (Reeve et al., 2019b), and the relationship sleep has to 
psychosis and mood symptomatology (Freeman et al., 2009, Freeman et al., 2012, Reeve et 
al., 2015). They identified the limitations of current offered sleep interventions and the need 
for additional interventions (Waite et al., 2020). Keyworkers described their beliefs and 
concerns about Sleepio. Allan et al. (2019) found that clinicians expressed similar concerns 
about the EMPOWER digital intervention for relapse management in psychosis as potentially 
increasing paranoia. Increased paranoia is one possible outcome of digital intervention for 
psychosis (Eisner et al., 2019). Keyworkers anticipated service user autonomy to be an 
important mechanism in Sleepio intervention. Other studies of digital interventions in 
80 
 
psychosis have found that improved self-management is an outcome of digital applications 
(Berry et al., 2019, Eisner et al., 2019, Huerta-Ramos et al., 2016). 
Keyworkers suggested service user facilitators and barriers to the intervention. They 
identified applying their own eligibility criteria when considering referrals; for example 
perceived stability and likelihood of engagement. Kingdon and Kirschen (2006) found that 
beliefs about service user engagement impact on whether psychological interventions are 
offered to people affected by psychosis. The impact of service user comfort with technology 
and service user stability that were considered in our study were also identified as facilitators 
and barriers to the implementation of the EMPOWER digital intervention (Allan et al., 2019).  
Lastly, we developed an understanding of service level facilitators and barriers to 
implementation of Sleepio. Similarly to themes resulting from our analysis, clinicians in the 
EMPOWER implementation trial expressed concerns that the application was not sufficiently 
person-centred and believed that restricted resources would impact on its implementation 
(Allan et al., 2019). Palmier-Claus et al. (2013) also found that service user participants were 
concerned that a digital monitoring application would reduce the person-centred elements 
of their care. 
2.6.3. Preliminary Logic Model 
Our preliminary logic model incorporates findings from our data with theorised mechanisms 
and outcomes. As the model was largely informed by clinician perspectives, the preliminary 
model should be understood as being through this lens rather than being from the 
perspectives of multiple stakeholders. Certain features are therefore likely to be 
underdeveloped, for example implementation facilitators and barriers, hypothesised 
mechanisms, and outcomes from the perspective of service users.  
The hypothesised mechanisms of the intervention were developed from CBTi literature and 
qualitative data. Qualitative data suggested that keyworkers anticipate reduced distress 
around sleep and reduced fear of relapse. Known CBTi mechanisms include increased 
knowledge about sleep, behavioural changes such as decreased time in bed, decreased 
napping, and consistent sleep scheduling (Maurer et al., 2021, Schwartz and Carney, 2012), 
cognitive changes, such as decreased unhelpful beliefs and attitudes around sleep, increased 
internal sleep locus of control, and increased self-efficacy regarding sleep (Chow et al., 2018, 
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Eidelman et al., 2016, Schwartz and Carney, 2012), and changes to physiological and cognitive 
arousal levels (Schwartz and Carney, 2012). Interviews also revealed hypothesised adverse 
effects represented in the model, including increased paranoia, unhelpful sleep monitoring 
behaviours, increased distress about sleep, and increased fear of relapse. From the literature, 
we can also hypothesise that decreased sleep time, increased sleepiness, deterioration in 
functioning, and poorer mood may occur for some people during intervention (Kyle et al., 
2011).  
2.6.4. Strengths and Limitations 
One strength of the presented work is its design. Process evaluations have been used 
previously to consider the implementation of digital interventions in psychosis (Allan et al., 
2019, Berry et al., 2019). The MRC process evaluations framework for complex interventions 
highlights the importance of integrating mixed-methods results from process evaluations to 
better understand what is observed within clinical trials (Moore et al., 2015). Deaton and 
Cartwright (2018) argue that randomised clinical trials are neither sufficient in understanding 
the implementation of a complex intervention nor to lead to practical clinical implementation, 
and should be supplemented by the use of implementation methodology. Our methodology 
allows us to fully understand the implementation of Sleepio and inform future clinical efficacy 
trials (Greenhalgh, 2017).  
As above, one crucial limitation was that qualitative data included only clinicians’ 
perspectives. This limits the logic model to representing only facilitators and barriers through 
the clinician stance and lens and as such is inherently incomplete in its understanding of the 
factors and stakeholders influencing implementation. In the planned overarching study, we 
plan to incorporate service user and keyworker perspectives prior to and following Sleepio 
intervention. Berry et al. (2019) noted the importance of qualitative investigations taking 
place prior to and during the implementation of a complex intervention, as opposed to only 
afterwards, as this allows the implementation to be guided by findings. The outcomes of our 
study could, for example, guide training in FEP services regarding sleep and Sleepio. We also 
contribute to the wider understanding of how digital interventions can be implemented in 
psychosis services (Ben-Zeev et al., 2012). Stakeholder perspectives on implementation of 
digital interventions in psychosis are currently underrepresented in the research (Bucci et al., 
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2018) and are critical to the implementation of optimised interventions (Biagianti et al., 2017). 
At present, we provide data from only one stakeholder group.  
The presented work comprises preliminary data of implementation factors and 
characterisation of service users. We recruited from a single healthboard FEP service. As a 
result of this and of our contextual constructionism stance the resulting qualitative 
framework and logic model may not be generalisable. The use of non-probablistic sampling is 
likely to bias our qualitative dataset; as those who volunteered may hold particular views 
about Sleepio implementation. Additionally, consenting service users were limited to people 
with devices and internet access. This is likely to exclude people in the FEP population from 
participation, and biases the participant sample. At present, consenting service users are 
homogenous in their self-identified ethnicity and do not represent the underlying population 
of people experiencing FEP (Bresnahan et al., 2007). This limits the applicability of the 
resulting logic model in the service and generally, as this may not take into account 
symptomatology, usage characteristics, facilitators and barriers experienced by people of 
minority ethnicity.  
Our qualitative sample was relatively small, as it was limited by keyworker uptake. Results 
should be interpreted carefully, particularly considering the epistemological stance taken. 
Hennink et al. (2017) concluded that conventional saturation in qualitative data is reached at 
nine participants, but 16-24 provide comprehensive saturation. However, Young and Casey 
(2019) have suggested that our sample size is sufficient in capturing themes. Crucially, no 
service user consented to take part in qualitative interviews. This limits the scope of the 
preliminary logic model and restricts its interpretation to representing the factors acting upon 
the implementation of Sleepio through the lens of clinicians and the service. It is also likely 
that researcher FR’s position as a clinician within the service biases the dataset and 
interpretations made. As such, these limitations are explicitly considered in our analysis 
methodology and epistemological position. Researcher FR conducted the majority of 
qualitative analysis. Whilst this could be considered adequate in the context of the doctoral 
project, the study would benefit from an iterative analysis of this data using a team approach. 
Such an approach would allow for a mix of experiences and perspectives to shape the 





This project has led to development of a preliminary logic model of the implementation of 
Sleepio in an NHS Scotland FEP service, which will inform the ongoing process evaluation. 
Planned further work will fully characterise implementation and provide outcome signals for 
the impacts of Sleepio intervention on symptomatology. Qualitative work will elucidate 
keyworker and service user perspectives on the Sleepio intervention prior to and following its 
use. It will be particularly important to recruit service users to interview, to develop the 
resulting logic model more fully from service users’ viewpoints.  
We can recommend that further awareness-raising about sleep difficulties, the project, and 
its inclusion/exclusion criteria are undertaken. Training should be provided; with a focus on 
diverse sleep difficulties and the relationship between sleep and psychosis. Keyworkers may 
benefit from sessions familiarising them with the Sleepio application. Opportunities should 
be given for keyworkers to meet with study researchers and informally discuss referrals. 
Referrals to the project are likely to fluctuate with service resource. This project will provide 
important information which may guide future clinical trials of Sleepio efficacy in the context 
of first episode psychosis. 
Future work should consider incorporating the views of other stakeholders including; family 
and friends, persons with lived experience of first episode services, and multidisciplinary 
professionals. Our understanding of Sleepio implementation would be greatly improved if 
similar research were undertaken in other first episode services across the United Kingdom. 





To our knowledge, this is the first exploration of the implementation of Sleepio in a first 
episode of psychosis service. We provide a preliminary and working logic model of this 
implementation which will be used to guide the development of the ongoing project and may 
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Appendix 1.3. Search Strategy 
 
TI AB used in EBSCOHost syntax (CINAHL and APA PsychInfo) 
ti,ab. used in Ovid syntax (MEDLINE R 1946 – Present and EMBASE 1947-Present) 
 
1. TI insomn* OR AB insomn*   
2. TI sleep maintain* OR AB sleep maintain*  
3. TI sleep initiat* OR AB sleep initiat*  
4. TI sleeplessness OR AB sleeplessness  
5. TI sleep OR AB sleep  
6. S1 OR S2 OR S3 OR S4 OR S5 (‘sleep’ – APA PsychInfo 74,896; CINAHL 66,220; Ovid 
MEDLINE R 156,612; Ovid EMBASE 294,485) 
 
7. TI schizo* OR AB schizo*  
8. TI Psychos?s OR AB Psychos?s  
9. TI psychotic OR AB psychotic  
10. TI Delus* OR AB Delus*  
11. TI Hallucinat* OR AB Hallucinat* 
12. S7 OR S8 OR S9 OR S10 OR S11 (‘psychosis’ – APA PsychInfo 185,665; CINAHL 45,032; 
Ovid MEDLINE R 176,523; Ovid EMBASE 286,353) 
 
13. TI "first episode" OR AB "first episode" 
14. TI "first-episode" OR AB "first-episode"  
15. TI “early psychosis” OR AB "early psychosis" 
16. S13 OR S14 OR S15 (‘early psychosis’ – APA PsychInfo 8,407; CINAHL 4,833; Ovid 




17. TI Prodrom* OR AB Prodrom* 
18. TI “ultra high risk” OR AB “ultra high risk”  
19. TI “ultra-high-risk” OR AB “ultra-high-risk”  
20. TI “at risk mental state” OR AB “at risk mental state” 
21. TI “at-risk-mental-state” OR AB “at-risk-mental-state”  
22. TI “clinical high risk” OR AB “clinical high risk”  
23. TI “clinical-high-risk” OR AB “clinical-high-risk” 
24. S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 (‘prodromal psychosis’ – APA 
PsychInfo 5,939; CINAHL 3,329; Ovid MEDLINE R 8,934; Ovid EMBASE 19,464) 
 
25. S6 AND S12 (‘sleep and psychosis’ – APA PsychInfo 4,460; CINAHL 1,197; Ovid 
MEDLINE R 3,772; Ovid EMBASE 9,091) 
26.  S12 OR S16 OR S24 (‘all psychosis’ - APA PsychInfo 189,290; CINAHL 48,459; Ovid 
MEDLINE R 182,241; Ovid EMBASE 297,206) 
27. S6 AND S26 (‘sleep and all psychosis’ – APA PsychInfo 4,745; CINAHL 1,405; Ovid 




Appendix 1.4. Data Extraction Proforma 
 
Authors   
Authors Abbrev   
Year   
Title   
Study Type   
Whole or Part Sample   
Country   
Total Sample n   
Psychosis Sample n   
Age 
Mean   
SD   
Median   
Range   
Gender/Sex   
Race/Ethnicity   
Diagnoses   
How diagnosis defined   
Participant Care Context   
How Insomnia Identified   
Insomnia Prevalence 
Overall   
DIS Prevalence   
DMS Prevalence   
EMA Prevalence   
ISI Mild   
ISI Moderate   
ISI Severe   
How Symptoms Measured   
Relationship to Symptoms   

















Appendix 1.7. Critical Appraisal of Prevalence Studies 
 
Table 7. Quality ratings based on JBI Checklist for Prevalence Studies. 
 
Authors in grey reflect those co-rated by FR and HL. 
  
Sample frame 









Analysis conducted w 
sufficient coverage 
of identified sample?
Batalla-Martin et al., 2020 Yes Unclear Yes Yes Yes
Freeman et al. 2009 Yes Unclear No Yes Yes
Hou et al., 2017 Yes Yes Yes Yes Yes
Mondal et al., 2018 Yes Yes Yes Yes Yes
Ogbolu et al., 2012 Yes No Yes Yes Yes
Palmese et al., 2011 Yes Unclear No Yes Yes
Reeve et al., 2019 Yes Unclear No Yes Yes
Seow et al., 2018 Yes No Yes Yes Yes
Subramaniam et al., 2018 Yes No Yes Yes Yes













Batalla-Martin et al., 2020 Yes No Yes Unclear 0.67
Freeman et al. 2009 Yes Unclear No Unclear 0.44
Hou et al., 2017 No Yes No Yes 0.78
Mondal et al., 2018 Unclear Unclear No Unclear 0.56
Ogbolu et al., 2012 Yes Yes No Yes 0.78
Palmese et al., 2011 Yes Yes No Unclear 0.56
Reeve et al., 2019 Yes Unclear No Unclear 0.56
Seow et al., 2018 Yes No No Unclear 0.56
Subramaniam et al., 2018 Yes No No No 0.56
Xiang et al., 2009 No Yes No Yes 0.78
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Appendix 1.8. Critical Appraisal of Analytical Cross-Sectional Studies 
 
Table 8. Quality ratings based on JBI Checklist for Cross-Sectional Studies.  
 
Authors in grey reflect those co-rated by FR and HL.  
Inclusion criteria
clearly defined?
Subjects and setting 
described in detail?
Insomnia measured 





Batalla-Martin et al., 2020 Yes Yes Yes Yes
Freeman et al., 2009 Yes Yes Yes Yes
Freeman et al., 2019 Yes Yes Yes Yes
Grezellschak et al., 2017 Yes No Yes No
Hou et al., 2017 Yes Yes No Yes
Li et al., 2016 Yes Yes Unclear Yes
Li et al., 2017 Yes Yes No Yes
Miller et al., 2019 Yes Yes Yes Yes
Miller et al., 2020 Yes Yes Yes Yes
Miller et al., 2021 Yes Yes No Yes
Palmese et al., 2011 No Yes Yes Yes
Reeve et al., 2018 Yes Yes Yes Yes
Reeve et al., 2019 Yes Yes Yes Yes
Seow et al., 2018 Yes Yes Yes Yes
Subramaniam et al., 2018 Yes Yes Yes Yes















Batalla-Martin et al., 2020 Yes No Yes Unclear 0.75
Freeman et al., 2009 Yes Yes Yes Yes 1
Freeman et al., 2019 No No Yes Yes 0.75
Grezellschak et al., 2017 Yes No Yes Yes 0.625
Hou et al., 2017 Yes Yes Yes Yes 0.875
Li et al., 2016 Yes Yes No Yes 0.75
Li et al., 2017 Yes Yes Yes Yes 0.875
Miller et al., 2019 Yes Yes Yes Yes 1
Miller et al., 2020 Yes Yes Yes Yes 1
Miller et al., 2021 Yes Yes Yes Yes 0.875
Palmese et al., 2011 No No Yes Unclear 0.5
Reeve et al., 2018 No Unclear Yes Yes 0.75
Reeve et al., 2019 No Unclear Yes Yes 0.75
Seow et al., 2018 No No Yes Yes 0.75
Subramaniam et al., 2018 Yes Yes Yes Yes 1
Xiang et al., 2009 Yes Yes Yes Yes 0.875
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Appendix 1.9. Meta Analysis Supplementary Results  
1.9.1. Supplementary results for studies aiming to establish prevalence  
 
 
Figure 7. Funnel plot for studies aiming to establish prevalence 
 
1.9.1.1. Random-effects model across studies aiming to establish prevalence 
 
Table 9. Random-effects results for studies aiming to establish prevalence 
 
Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.232209738 0.183390159 0.284874352 10.54347436
Freeman et al., 2009 0.6 0.417766967 0.769627425 8.114914257
Hou et al., 2017 0.288924559 0.253964116 0.32518535 10.78054104
Mondal et al., 2018 0.75 0.669669608 0.822618083 10.09682381
Ogbolu et al., 2012 0.106060606 0.041447291 0.193520966 9.444086851
Palmese et al., 2011 0.48 0.406154229 0.554283426 10.33481879
Reeve et al., 2019 0.5 0.373295155 0.626704845 9.315879037
Seow et al., 2018 0.25 0.17623746 0.33173089 10.0703334
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 10.56093734
Xiang et al., 2009 0.36039604 0.319036224 0.402816637 10.73819112
Pooled 0.365418577 0.272162144 0.463950503 100
Statistics






1.9.1.2. Quality-effects model across studies aiming to establish prevalence 
 
Figure 8. Quality-effects forest plot for studies aiming to establish prevalence 
Table 10. Quality-effects results for studies aiming to establish prevalence 
 
 
Study Prevalence LCI 95% HCI 95% weight (%)
Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.232209738 0.183390159 0.284874352 11.44903392
Freeman et al., 2009 0.6 0.417766967 0.769627425 1.624323199
Hou et al., 2017 0.288924559 0.253964116 0.32518535 29.15134998
Mondal et al., 2018 0.75 0.669669608 0.822618083 5.009235282
Ogbolu et al., 2012 0.106060606 0.041447291 0.193520966 4.439726201
Palmese et al., 2011 0.48 0.406154229 0.554283426 6.625409702
Reeve et al., 2019 0.5 0.373295155 0.626704845 2.981094834
Seow et al., 2018 0.25 0.17623746 0.33173089 4.882476504
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 9.921137932
Xiang et al., 2009 0.36039604 0.319036224 0.402816637 23.91621245
Pooled 0.323547813 0.208698332 0.449884987 100
Statistics






1.9.1.3. Fixed-effects model across studies aiming to establish prevalence 
 
 
Figure 9. Fixed-effects forest plot for studies aiming to establish prevalence 
 
Table 11. Fixed-effects results for studies aiming to establish prevalence 
 
Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.232209738 0.183390159 0.284874352 11.86779059
Freeman et al., 2009 0.6 0.417766967 0.769627425 1.353149956
Hou et al., 2017 0.288924559 0.253964116 0.32518535 27.66193434
Mondal et al., 2018 0.75 0.669669608 0.822618083 5.523513753
Ogbolu et al., 2012 0.106060606 0.041447291 0.193520966 2.950310559
Palmese et al., 2011 0.48 0.406154229 0.554283426 7.786157941
Reeve et al., 2019 0.5 0.373295155 0.626704845 2.684117125
Seow et al., 2018 0.25 0.17623746 0.33173089 5.346051464
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 12.40017746
Xiang et al., 2009 0.36039604 0.319036224 0.402816637 22.42679681
Pooled 0.329453848 0.310191312 0.349007002 100
Statistics





1.9.2. Supplementary results for all studies reporting prevalence 
 
Figure 10. Funnel plot for all studies reporting prevalence 
 
1.9.2.1. Random-effects model across all studies reporting prevalence 
 
Table 12. Random-effects results for studies reporting prevalence 
 
Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.232209738 0.183390159 0.284874352 6.860758982
Freeman et al., 2009 0.6 0.417766967 0.769627425 5.258276514
Freeman et al., 2019 0.501109878 0.478021779 0.524195611 7.097819606
Hou et al., 2017 0.288924559 0.253964116 0.32518535 7.017912034
Li et al., 2016 0.193298969 0.155452031 0.234178213 6.945599922
Li et al., 2017 0.289215686 0.253936375 0.325816872 7.015743408
Miller et al., 2020 0.176829268 0.137327398 0.220109866 6.911090777
Miller et al., 2021 0.449832776 0.410113681 0.489873838 7.012870112
Mondal et al., 2018 0.75 0.669669608 0.822618083 6.565022915
Ogbolu et al., 2012 0.106060606 0.041447291 0.193520966 6.133657105
Palmese et al., 2011 0.48 0.406154229 0.554283426 6.722546932
Reeve et al., 2019 0.5 0.373295155 0.626704845 6.049044804
Seow et al., 2018 0.25 0.17623746 0.33173089 6.547497506
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 6.872330887
Xiang et al., 2009 0.36039604 0.319036224 0.402816637 6.989828497
Pooled 0.347945741 0.274133262 0.425570642 100
Statistics






1.9.2.2. Quality-effects model across all studies reporting prevalence 
 
 
Figure 11. Quality-effects forest plot for all studies reporting prevalence 
 
Table 13. Quality-effects results for all studies reporting prevalence 
 
Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.232209738 0.183390159 0.284874352 4.478649124
Freeman et al., 2009 0.6 0.417766967 0.769627425 1.225663596
Freeman et al., 2019 0.501109878 0.478021779 0.524195611 24.27567635
Hou et al., 2017 0.288924559 0.253964116 0.32518535 9.851857942
Li et al., 2016 0.193298969 0.155452031 0.234178213 6.554897677
Li et al., 2017 0.289215686 0.253936375 0.325816872 10.92250804
Miller et al., 2020 0.176829268 0.137327398 0.220109866 7.737273545
Miller et al., 2021 0.449832776 0.410113681 0.489873838 10.71781257
Mondal et al., 2018 0.75 0.669669608 0.822618083 2.404704146
Ogbolu et al., 2012 0.106060606 0.041447291 0.193520966 2.612786638
Palmese et al., 2011 0.48 0.406154229 0.554283426 2.878149435
Reeve et al., 2019 0.5 0.373295155 0.626704845 1.810576724
Seow et al., 2018 0.25 0.17623746 0.33173089 2.367571182
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 3.843606495
Xiang et al., 2009 0.36039604 0.319036224 0.402816637 8.318266535
Pooled 0.355218609 0.260323012 0.456096272 100
Statistics






1.9.2.3. Fixed-effects model across all studies reporting prevalence 
 
Figure 12. Fixed-effects forest plot for all studies reporting prevalence 
  




Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.232209738 0.183390159 0.284874352 4.469880525
Freeman et al., 2009 0.6 0.417766967 0.769627425 0.509649929
Freeman et al., 2019 0.501109878 0.478021779 0.524195611 30.11947531
Hou et al., 2017 0.288924559 0.253964116 0.32518535 10.41858134
Li et al., 2016 0.193298969 0.155452031 0.234178213 6.491770407
Li et al., 2017 0.289215686 0.253936375 0.325816872 10.23477316
Miller et al., 2020 0.176829268 0.137327398 0.220109866 5.489180383
Miller et al., 2021 0.449832776 0.410113681 0.489873838 10.00083549
Mondal et al., 2018 0.75 0.669669608 0.822618083 2.0803743
Ogbolu et al., 2012 0.106060606 0.041447291 0.193520966 1.111203944
Palmese et al., 2011 0.48 0.406154229 0.554283426 2.932575821
Reeve et al., 2019 0.5 0.373295155 0.626704845 1.010944941
Seow et al., 2018 0.25 0.17623746 0.33173089 2.013534965
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 4.67039853
Xiang et al., 2009 0.36039604 0.319036224 0.402816637 8.446820954
Pooled 0.368520024 0.356339272 0.380785169 100
Statistics





1.9.3. Supplementary results for studies using the ISI 
 
 
Figure 13. Funnel plot for studies using the ISI 
1.9.3.1. Random-effects model across studies using the ISI 
 
Table 15. Random-effects results for studies using the ISI 
 
  
Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.411985019 0.353549191 0.471684552 14.6886887
Freeman et al., 2009 0.833333333 0.675560403 0.948750851 12.08308248
Freeman et al., 2019 0.501109878 0.478021779 0.524195611 15.04422627
Miller et al., 2020 0.176829268 0.137327398 0.220109866 14.76477454
Mondal et al., 2018 0.669354839 0.583788909 0.749696806 14.23495067
Palmese et al., 2011 0.48 0.406154229 0.554283426 14.47806666
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 14.70621067
Pooled 0.456150657 0.319548503 0.596068842 100
Statistics






1.9.3.2. Quality-effects model across studies using the ISI 
 
Figure 14. Prevalence of insomnia across studies using the ISI, quality effects forest plot 
 
Table 16. Quality-effects results for studies using the ISI 
 
 
1.9.3.3. Fixed-effects model across studies using the ISI 
 
Figure 15. Fixed-effects forest plot for studies using the ISI 
Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.411985019 0.353549191 0.471684552 9.912881464
Freeman et al., 2009 0.833333333 0.675560403 0.948750851 3.107396573
Freeman et al., 2019 0.501109878 0.478021779 0.524195611 49.41856968
Miller et al., 2020 0.176829268 0.137327398 0.220109866 16.8969107
Mondal et al., 2018 0.669354839 0.583788909 0.749696806 5.620068293
Palmese et al., 2011 0.48 0.406154229 0.554283426 6.561844372
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 8.482328925
Pooled 0.424823093 0.235541429 0.625406157 100
Statistics







Table 17. Fixed-effects results for studies using the ISI 
 
  
Study Prevalence LCI 95% HCI 95% weight (%)
Batalla-Martin et al., 2020 0.411985019 0.353549191 0.471684552 8.891474157
Freeman et al., 2009 0.833333333 0.675560403 0.948750851 1.01379425
Freeman et al., 2019 0.501109878 0.478021779 0.524195611 59.9135782
Miller et al., 2020 0.176829268 0.137327398 0.220109866 10.91906266
Mondal et al., 2018 0.669354839 0.583788909 0.749696806 4.138274888
Palmese et al., 2011 0.48 0.406154229 0.554283426 5.83347183
Subramaniam et al., 2018 0.225806452 0.178536133 0.276844743 9.290344025
Pooled 0.437377605 0.419689406 0.455145757 100
Statistics

















Appendix 2.2. Approved Proposal for Major Research Project 
 
Abstract 
Background: Covid-19 lockdown regulations impact negatively on sleep and mental health. These 
impacts disproportionately affect individuals with pre-existing mental health difficulties. Sleep 
disorders, particularly insomnia, are common in first episode psychosis (FEP) and are associated with 
increased symptomatology. Cognitive Behavioural Therapy is effective in treating insomnia (CBTi). 
Pilot research suggests that insomnia is a tractable clinical target in psychosis. Digital CBTi reduces 
both insomnia and paranoia, offering a non-contact intervention during Covid-19 lockdown and its 
aftermath.  
Aims: i) characterise the process of implementing a referrals pathway for Sleepio, ii) consider the 
expectations of service users and service keyworkers regarding digital sleep intervention and iii) 
characterise service users beginning sleep intervention.  
Methods: People experiencing a FEP and insomnia will be eligible to access Sleepio intervention. 
Service users and keyworkers will be invited to participate in semi-structured interviews to elicit their 
views of Sleepio implementation. Recruitment into the study will be monitored. Measures will 
examine changes in psychosis, insomnia, and mood symptomatology, and Covid-19-related worry at 
baseline.  
Results: We will analyse qualitative interview data of the expectations of service users and keyworkers 
of the Sleepio intervention. A framework analysis will be used to analyse themes arising from 
interviews. Recruitment data will be summarised. We will characterise service users’ pre-intervention 
psychosis symptomatology, insomnia, mood, Covid-19-related worry, and the relationships between 
these. We will consider how these data inform a login model of Sleepio implementation.  
Practical Applications: The overarching study aims to develop a logic model to support future 
implementation of Sleepio in FEP services. The major research project act as an internal pilot and will 





1. Introduction  
Following the emergence of severe acute respiratory syndrome Coronavirus 19 (Covid-19), UK 
governments introduced regulations in order to protect public health. In Scotland, the Health 
Protection (Coronavirus) (Restrictions) (Scotland) Regulations 2020 implemented measures to 
prevent, control and mitigate the spread of infection (Scottish Government, 2020a). These included 
requirements for individuals to have contact only with those in their household, stay 2 metres apart 
from others, and only leave home for approved reasons. Potentially infected individuals were required 
to quarantine. The Coronavirus Scotland Act amended the responsibilities of health and social care 
organisations to the populations they serve (Scottish Government, 2020b). The presence of Covid-19, 
quarantine, restrictions to normal life and impacts on health and social care provision bring challenges 
to population mental health.  
Quarantine and physical distancing measures in response to epidemics impact on the psychological 
health of the population (Brooks et al., 2020; Hossain, Sultana & Purohit, 2020). Systematic reviews 
suggest regulations raise the incidence of insomnia, low mood, post-traumatic stress (PTSD), 
avoidance of other people and of illness symptoms (e.g. coughs or sneezes; Brooks et al., 2020; 
Hossain et al., 2020). Previous mental illness diagnosis, higher fear of infection, being a healthcare 
worker, loss of routine, and lack of supplies access are associated with worse psychological outcomes 
(Brooks et al., 2020). Research emerging from the Covid-19 pandemic in China and Italy (both of which 
imposed population-wide quarantine) has found increased anxiety and depression symptoms, poor 
sleep quality, and general psychological distress (Casagrande et al., 2020; Yan & Huang, 2020). In Italy, 
anxiety, poor sleep, and psychological distress were together predictive of Covid-19-related PTSD 
symptomatology (Casagrande et al., 2020).  
In Scotland, Covid-19 is anticipated to reduce psychological wellbeing and increase sleep disorder, 
particularly in those with pre-existing mental health difficulties (Public Health Scotland, 2020). There 
is an increased opportunity and need for digital psychological interventions, delivered remotely. 
Particular subpopulations are likely to be disproportionately affected by the psychological impacts of 
Covid-19, such as those who live in deprived areas, the elderly, people with disabilities, and people 
with pre-existing mental health conditions. People recovering from a first episode of psychosis (FEP) 
are one such group. This population typically present with mental, physical and social comorbidities 
(Gates et al., 2015), which may further increase their vulnerability.  
Sleep difficulties, particularly insomnia, are common in people recovering from a FEP (~50% affected; 
Davies et al., 2017; Reeve, Sheaves & Freeman, 2018a). In people affected by psychosis, severity of 
sleep disorder is related to flattened affect, increased hallucinations, and paranoia, and mood disorder 
(Davies et al., 2017; Reeve et al., 2018a; Villa et al., 2018; Reeve et al., 2018b). Models of paranoia 
development suggest that mood disorder (anxiety, depression and worry) contributes to the 
development of paranoia, which is then heightened by insomnia (Freeman et al., 2009; Reeve, Sheaves 
& Freeman, 2015). Insomnia can also occur due to the impact of psychosis symptomatology. In the 
current context of Covid-19, related worry and governmental regulations based on Covid-19, sleep 
may deteriorate in this group, impacting on psychosis symptomatology and other mental health 
variables.  
Insomnia is a tractable clinical target in this population, for which intervention shows promising 
results. Case series and pilot studies investigating CBTi in psychosis populations found it produced 
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clinically significant reductions in insomnia but mixed impacts on psychosis symptomatology (Freeman 
et al., 2015; Myers, Startup & Freeman, 2011). Cognitive Behavioural Therapy targeting Insomnia 
Disorder can be effectively delivered using digital applications (dCBTi), with a comparative efficacy to 
1-1 CBTi (Espie et al., 2012). Sleepio, a dCBTi application has been shown to reduce hallucinations and 
paranoia in a large non-clinical population (Freeman et al., 2017). Additionally, digital application-
based interventions have been increasingly used in FEP populations (Rus-Calafell & Schneider, 2020).  
Sleepio therefore provides a psychotherapeutic intervention which can be offered remotely in the 
current context of Covid-19. This intervention targets one of the most common comorbid difficulties 
in FEP, a common psychological impact of pandemic-related regulations, and may demonstrate effects 
on wider psychological wellbeing in this population. 




2. Aims and Questions 
Informed by the Medical Research Council process evaluation for complex interventions framework 
(Moore et al., 2015); the overarching research study aims to develop a logic model of Sleepio 
implementation in people recovering from FEP, in the context of Covid-19 restrictions and their 
aftermath. This Major Research Project (MRP) aims to act as an internal pilot; providing initial 
qualitative and quantitative data towards this implementation study.  
We will assess: 
2.1. Implementation  
1) What is the pathway of approval for researching Sleepio in the context of an early 
psychosis service?  
i. Data protection approvals 
ii. Ethical approvals 
iii. Management approvals 
iv. Contracting between involved parties 
2) How was the referral pathway established and how are recruitment efforts 
undertaken?  
i. Presentations to the esteem service 
ii. Meetings with local area teams 
iii. Discussion with keyworkers about study design, eligibility, potential 
participants 
3) What is the initial rate of eligibility for the study? 
4) What is the initial rate of consent into the study?  
 
2.2. Symptomatology Measures 
At baseline: 
1) What are the characteristics of participants’ insomnia? 
2) What are the characteristics of participants’ psychotic symptomatology? 
3) What are the characteristics of participants’ mood? 
4) What are the characteristics of participants/ Covid-19-related worry? 
 




2.3. Staff and Service User Expectations 
1) What are staff expectations of Sleepio implementation? 
2) What are service user expectations of Sleepio implementation? 
3) How do staff and service user views compare and contrast?  
 




Figure 1. Key functions of process evaluation and relations among them from MRC Complex 
Interventions guidance. 
From these data, we aim to begin to develop a logic model for the implementation of Sleepio 
intervention in FEP services. This model will graphically represent the hypothesized context and the 
process of implementing Sleepio in the Esteem service. Further work following this MRP will further 
elucidate the mechanisms of Sleepio’s impact, outcomes and other factors acting upon the model 





3. Plan of Investigation 
3.1. Participants 
3.1.1 Service users of the Esteem FEP service, NHS Greater Glasgow and Clyde (NHSGGC).  
3.1.2 Esteem keyworkers. 
 
3.2. Inclusion and Exclusion Criteria (Service Users) 
3.2.1 Inclusion: 
 
3.2.1.1    Service users under the care of Esteem First Episode Psychosis Service in NHS GGC 
3.2.1.2    Aged >=16yrs and ≤35 years (service criteria) 
3.2.2.3    Potentially affected by Insomnia Disorder (defined by SCI-02 score ≤2) 




3.2.2.1    Moderate to severe learning disability 
3.2.2.2    Acutely unwell (recent contact with crisis team or hospitalization) 
3.2.2.3    Incapacity to provide informed consent 
3.2.2.4    Insufficient English to access intervention 
3.2.2.5    Organic impairment 
3.2.2.6    No access to an appropriate device  
 
3.3. Design 
The proposed study is a prospective, non-randomised trial of the implementation of Sleepio in the 
context of an FEP service. 
 
3.4. Study Procedures 
Study protocol will be presented at the Esteem journal club and each area multidisciplinary team 
meeting (FR).  
3.4.1. Service User Participants 
Keyworkers in Esteem FEP services will be offered the opportunity to meet with researcher FR to learn 
about the study and consider service users who may benefit (FR).  
Service users will be provided with an information leaflet regarding the study. Those who wish to 
participate can contact the study email address or ask their keyworker to do so on their behalf. They 
will be sent an easy-read Participant Information Sheet and Consent Form (FR). Participants will 
complete consenting processes on Attend Anywhere videocall (FR) and will return signed Consent 
Forms. Participants will then complete the Sleep Condition Indicator-2 item (SCI-02; Espie et al., 2016) 
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insomnia screening tool (FR). Where their score indicates that they may be affected by insomnia, they 
will be eligible to participate.  
If participants have indicated they would like to participate in an interview, they will be invited to 
share their expectations of Sleepio intervention at a Microsoft Teams meeting lasting 45 - 60 minutes 
(FR). Semi-structured interviews will be digitally recorded and transcribed for purposes of analysis 
(FR). They will be analysed using a framework analysis (FR).  
FR and LB will meet with participants and complete baseline measures using Attend Anywhere and 
Online Surveys (https://www.onlinesurveys.ac.uk/). This appointment will also allow participants to 
set up the Sleepio application and complete its initial assessment.  
The following service user procedures will occur after the timeline of the MRP: 
The intervention period will commence. Participant adherence to and attrition from intervention will 
be collated via the Sleepio application (LB).  
10 weeks following baseline assessment, participants will be invited to repeat symptomatology 
measures at an Attend Anywhere appointment using Online Surveys (LB).  
Participants who have consented to being interviewed about their experience of Sleepio will be invited 
to participate in a further Microsoft Teams meeting (LB). Participants will be purposively sampled to 
include a range of participants reflecting their engagement with the Sleepio App. Semi-structured 
interviews will be digitally recorded and transcribed for purposes of analysis (LB). They will be analysed 
using a framework analysis (LB). 
 
3.4.2. Staff Participants 
Keyworkers in Esteem will be provided with an information leaflet describing the study (FR). This will 
detail i) service user eligibility criteria, and the pathway for recruiting service users into the study and 
ii) the role of keyworkers as participants.  
Keyworkers will be given the opportunity to participate in semi-structured interviews about their 
expectations of Sleepio, barriers and facilitators via Microsoft Teams meeting (FR). These will take 
place prior to service users beginning intervention. They will be provided with a Participant 
Information Sheet and Consent Form. Participating keyworkers will complete consenting processes on 
this videocall and will return signed Consent Forms (FR).  
The following keyworker procedures will occur after the timeline of the MRP: 
Following the intervention period, keyworkers will be offered participation in a further interview with 
another researcher (LB) about their experiences of Sleepio.  
Semi-structured interviews will be digitally recorded and transcribed for purposes of analysis and 
analysed using a framework analysis (FR; LB). 
 
3.5. Intervention and TAU 
3.5.1. Sleepio Intervention 
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Sleepio is a dCBTi application with a strong evidence base (Espie et al., 2019). The application is 
composed of six 20-minute sessions, unlocked weekly. It can be accessed via web browser or 
smartphone. Participants complete an initial assessment and choose a goal, which drives 
personalisation. Sleepio’s components are common to CBTi interventions: i) psychoeducation on sleep 
hygiene and processes; ii) cognitive components including restructuring, mindfulness, positive 
imagery, paradoxical intention training (trying to stay awake), and resolving thoughts about one’s day; 
and iii) behavioural components including sleep restriction, stimulus control, and relaxation 
techniques.  Participants are prompted to complete sessions and enter sleep data. Sleepio’s algorithm 
tailors ongoing intervention based on entered data and information about participants’ physical and 
mental health. Sleepio also provides access to online psychoeducation and a moderated user forum. 
3.5.2. Treatment as Usual (TAU) 
TAU will be free to vary during the study. TAU may comprise elements of sleep intervention. TAU is 
likely to be significantly different during Covid-19 restrictions. 
 
3.6. Measures  
• Demographic data (gender, age, ethnicity). 
3.6.1. Implementation Measures  
3.6.1.1. Time taken to procure necessary approvals (data protection, ethical, contracts).  
3.6.1.2. Number of presentations to Esteem  
3.6.1.3. Number of information sessions delivered to Esteem local area teams 
3.6.1.4. Number of meetings with service keyworkers 
3.6.1.5  Rate of referral 
3.6.1.6. Rate of eligibility to participate.  
3.6.1.7. Rate of consent to participation. 
3.6.1.8. Proportion completing Sleepio initial assessment. 
 
3.6.2. Symptomatology Measures 
Insomnia 
• Insomnia Severity Index (ISI, Morrin et al., 2011).  
Psychosis 
• Specific Psychotic Experiences Questionnaire; hallucinations subscale (SPEQ-H, Ronald et al., 
2014). 
• Revised Green et al Paranoid Thought Scales (R-GPTS, Freeman et al., 2019). 
Mood 
• Depression, Anxiety, and Stress Scales, 24 item (DASS-24, Lovibond and Lovibond, 1995). 
Covid-19 Anxiety  
• Fear of COVID-19 Scale (Ahorsu et al., 2020). 
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3.6.3. Qualitative Data 
• Semi-structured interviews exploring staff expectations for dCBTi intervention 
• Semi-structured interviews exploring service user expectations for dCBTi intervention 
3.7. Settings and Equipment 
The study will take place with service users of the NHSGGC Esteem FEP Service. Measures assessment 
will be undertaken on Attend Anywhere. Interviews will be recorded and transcribed using NHS GGC 
Microsoft Teams or an encrypted recording device. 
3.8. Sample Size 
This is a mixed-methods study focused on implementation. Formal sample size calculation would 
therefore not be appropriate. For the overall study, a target sample size of 40 service user participants 
is proposed, based on recruitment for 12 months. ~nine service users and ~nine keyworkers are hoped 
to be recruited for interviews. 
The MRP will aim to recruit ≥6 keyworkers and ≥3 service users.  
3.9. Data Analysis 
3.9.1. Quantitative 
Summary descriptive quantitative information will be provided for implementation measures.  
Symptomatology measurements will be quantitatively detailed (mean, median, range, variance). Our 
study is not designed nor powered to detect statistical differences in measures over time..  
3.9.2. Qualitative 
Information arising from qualitative interviews will analysed using a framework analysis based on the 
MRC Complex Interventions framework (Moore et al, 2016). This will comprise an iterative process of 
familiarization with the transcribed data, indexing to the thematic framework, identifying other 
emergent themes, charting and mapping, and summary interpretation.  
3.9.3. Modelling 
A logic model of Sleepio implementation in FEP services will begin to be developed from quantitative 
and qualitative data.  
3.9.4. Other  
A timeline of changes to Scottish government regulations regarding Covid19 will be collated in order 





4. Health and Safety Issues 
4.1. Researcher Safety Issues 
Use of Attend Anywhere in home environments may reveal researchers’ personal information. 
Researchers will ensure this is used in private spaces, will use blur background functions and will 
adhere to operation policy around its use.  
Recruitment, follow-up and data collection may require significant practical and emotional labour. 
Supervision, and time-management skills will be used to manage this. Researcher availability and 
monitoring of inboxes will be made clear to participants to maintain boundaries.    
4.2. Participant Safety Issues 
Prior to consenting, participants will be made aware that keyworkers will be informed of their 
participation. Researchers have a duty of care to report significant risks to a participant or to others 
to the mental health team in the event of a disclosure. These limitations to confidentiality will be made 
clear during consent processes. Researchers will ensure that appointments are undertaken in private 
spaces. 
Symptomatology measures and Sleepio intervention may be associated with emotional distress. 
Potential participants will be made aware of this prior to consenting. 





5. Ethical Issues 
Participation will not commence without informed consent, including ensuring participant awareness 
of confidentiality and limits to confidentiality. It will be made clear that study participation status will 
have no impact on TAU care. Aspects of the consent process will be optional - to participate in 
interviews pre- and post-intervention, for researchers to access participant SCI scores, and to discuss 
the participant’s use of Sleepio with their keyworker.  
Potential participants will be made aware that the study may comprise a risk of distress prior to 
consenting. Keyworkers will be informed of participating service users. Participants will be made 
aware of who to contact should they experience distress and the limits of confidentiality if there is risk 
to the participant or other persons. 
This study uses an application external to NHSGGC. A contract is in place between the University of 
Glasgow and NHS GGC (joint data controllers) and between the University of Glasgow and Big Health 
Ltd. The study will request approval from NHSGGC Information Governance, NHSGGC Research and 
Development and the NHS Research Ethics Committee. The study will analyse anonymised data 
outwith NHSGGC (at University of Glasgow). Data will be held in accordance with NHS GGC and 
University of Glasgow policies and GDPR.   
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6. Financial Considerations  
There will be no cost associated with Sleepio use for the purpose of this study.  
7. Dissemination 
An internal pilot of the study will be submitted as the Major Research Project for a Doctorate in Clinical 
Psychology at the University of Glasgow. Results will be presented to Esteem staff. The full project will 
be submitted for journal publication. Participating service users may receive a plain language summary 
of results if they wish. 
8. Practical Applications 
Digital CBT intervention presents a psychological intervention that can be offered under current 
conditions and is likely to be efficacious. Exploration and treatment of sleep disorders are intended 
to become part of TAU care in NHSGGC FEP services. A logic model of Sleepio implementation will 
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Appendix 2.7. Coding of Emergent Themes 
 
 
Figure 16. Example of framework analysis coding for categories and sub-categories 
